WO2008071394A1 - Abeta antibody parenteral formulation - Google Patents

Abeta antibody parenteral formulation Download PDF

Info

Publication number
WO2008071394A1
WO2008071394A1 PCT/EP2007/010825 EP2007010825W WO2008071394A1 WO 2008071394 A1 WO2008071394 A1 WO 2008071394A1 EP 2007010825 W EP2007010825 W EP 2007010825W WO 2008071394 A1 WO2008071394 A1 WO 2008071394A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
histidine
abeta antibody
formulation according
tween
Prior art date
Application number
PCT/EP2007/010825
Other languages
French (fr)
Inventor
Pierre Goldbach
Hanns-Christian Mahler
Robert Mueller
Christine Wurth
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39190366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008071394(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP07856573A priority Critical patent/EP2094729A1/en
Priority to BRPI0721097-3A priority patent/BRPI0721097A2/en
Priority to AU2007331712A priority patent/AU2007331712A1/en
Priority to KR1020097013954A priority patent/KR20090104017A/en
Priority to JP2009540650A priority patent/JP2010512356A/en
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to CA002671968A priority patent/CA2671968A1/en
Priority to US12/448,190 priority patent/US20110070225A1/en
Priority to MX2009006199A priority patent/MX2009006199A/en
Publication of WO2008071394A1 publication Critical patent/WO2008071394A1/en
Priority to IL198963A priority patent/IL198963A0/en
Priority to NO20092586A priority patent/NO20092586L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Definitions

  • the present invention relates to a stable pharmaceutical parenteral formulation of an antibody, antibody molecule, a mixture of antibodies and/or a mixture of antibody molecules against the amyloid-beta peptide (Abeta) and a process for the preparation thereof. Furthermore, corresponding uses are described.
  • the invention relates to a stable pharmaceutical parenteral Abeta antibody pharmaceutical formulation
  • a stable pharmaceutical parenteral Abeta antibody pharmaceutical formulation comprising: about 1 to about 250 mg/mL Abeta antibody; - about 0.001 to about 1% of at least one surfactant; about 1 to about 100 mM of a buffer; optionally about 10 to about 500 mM of a stabilizer and/or about 5 to about 500 mM of a tonicity agent; at a pH of about 4.0 to about 7.0.
  • the present invention relates to an Abeta antibody formulation wherein the comprised Abeta antibodies (or mixtures thereof) are capable of specifically binding the amyloid-beta peptide.
  • Antibodies that specifically bind Abeta are known in the art.
  • Specific examples of Abeta antibody that can be used in the formulation according to the invention have been described in the published PCT patent application WO 03/070760 and especially in the claims, the content of which is incorporated herein by reference.
  • amyloid-beta peptide which is also termed “amyloid ⁇ ", “A ⁇ ”, “A ⁇ 4" or “ ⁇ -A4" and, in particular in context of this invention "Abeta”, is a main component of the extracellular neuritic plaques that are associated with amyloidogenic diseases such as Alzheimer's disease; see Selkoe (1994), Ann. Rev. Cell Biol. 10, 373-403, Koo (1999), PNAS Vol. 96, pp. 9989-9990, US 4,666,829 or Glenner (1984), BBRC 12, 1131.
  • This amyloid ⁇ is derived from "Alzheimer precursor protein/ ⁇ -amyloid precursor protein” (APP).
  • APPs are integral membrane glycoproteins (see Sisodia (1992), PNAS Vol. 89, pp. 6075) and are endoproteolytically cleaved within the Abeta sequence by a plasma membrane protease, ⁇ -secretase (see Sisodia (1992), loc. cit.).
  • amyloid- ⁇ comprising either 39 amino acids (A ⁇ 39), 40 amino acids (A ⁇ 40), 42 amino acids (A ⁇ 42) or 43 amino acids (A ⁇ 43); see Sinha (1999), PNAS 96, 11094-1053; Price (1998), Science 282, 1078 to 1083; WO 00/72880 or Hardy (1997), TINS 20, 154.
  • a ⁇ has several naturally occurring forms, whereby the human forms are referred to as the above mentioned A ⁇ 39, A ⁇ 40, A ⁇ 41, A ⁇ 42 and A ⁇ 43.
  • the most prominent form, A ⁇ 42 has the amino acid sequence (starting from the N-terminus): DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA (SEQ ID NO: 3).
  • a ⁇ 41, A ⁇ 40, A ⁇ 39 the C-terminal amino acids A, LA and VIA are missing, respectively.
  • an additional threonine residue is comprised at the C-terminus of the above depicted sequence (SEQ ID NO: 3).
  • Antibody molecules as part of the group of protein pharmaceuticals, are very susceptible to physical and chemical degradation, such as denaturation and aggregation, deamidation, oxidation and hydrolysis.
  • Protein stability is influenced by the characteristics of the protein itself, e.g. the amino acid sequence, and by external influences, such as temperature, solvent pH, excipients, interfaces, or shear rates. So, it is important to define the optimal formulation conditions to protect the protein against degradation reactions during manufacturing, storage and administration.
  • One object of the present invention is to provide a formulation of an Abeta antibody or of mixtures of such antibodies, which is/are concentrated to the required concentration by reconstitution of a lyophilized formulation with a suitable volume or by removing the solvent by an ultrafiltration process.
  • the formulation demonstrates sufficient stability during manufacturing, storage and administration.
  • antibodies show an unpredictable viscosity-concentration profile. (Liu, J., M. D. Nguyen, et al. (2005).
  • Abeta antibodies that are useful in the present invention are immunoglobulin molecules, e.g. IgG molecules.
  • IgGs are characterized in comprising two heavy and two light chains (illustrated e.g. in figure 1) and these molecules comprise two antigen binding sites.
  • Said antigen binding sites comprise "variable regions" consisting of parts of the heavy chains (VH) and parts of the light chains (VL).
  • the antigen-binding sites are formed by the juxtaposition of the VH and VL domains.
  • the parenteral formulation of the present invention comprises Abeta antibody (or mixture of such antibodies) in which in at least one of the variable regions in the heavy chain of said antibodies comprises a N-glycosylation.
  • the glycosylated asparagine (Asn) in the variable region of the heavy chain (VH) may be in the complementarity determining region 2 (CDR2 region), said glycosylated asparagine (Asn) may be on position 52 in the variable region of the heavy chain (VH) as shown in SEQ ID NO: 1.
  • the term "mono-glycosylated antibody” relates to an antibody molecule comprising an N-glycosylation in one (V H )-region of an individual antibody molecule”; see also figure 1.
  • the term “double-glycosylation antibody” defines an antibody molecule which is N- glycosylated on both variable regions of the heavy chain” (figure 1).
  • Antibody molecules which lack a N-glycosylation on both heavy chain (VH)-domains are named “non- glycosylated antibodies” (figure 1).
  • the mono-glycosylated antibody, the double- glycosylated antibody and the non-glycosylated antibody may comprise the identical amino acid sequences or different amino acid sequences.
  • the mono-glycosylated antibody and the double-glycosylated antibody are herein referred to as "glycosylated antibody isoforms".
  • a purified antibody molecule characterized in that at least one antigen binding site comprises a glycosylation in the variable region of the heavy chain (VH) is a mono-glycosylated antibody which is free of or to a very low extent associated with an isoform selected from a double-glycosylated antibody and a non- glycosylated antibody, i.e. a "purified mono-glycosylated antibody".
  • a double-glycosylated antibody in context of this invention is free of or to a very low extent associated with an isoform selected from a mono-glycosylated antibody and a non-glycosylated antibody, i.e. a "purified double-glycosylated antibody".
  • the formulations according to this invention may contain mono-glycosylated or double-glycosylated or non-glycosylated antibodies, or specifically defined mixtures thereof.
  • the antibody mixtures or antibody pools provided herein may comprise 50% mono- glycosylated and 50% double-glycosylated antibodies as defined herein. However, also envisaged are the ratios of 30/70 to 70/30. Yet, the person skilled in the art is aware that also other ratios are envisaged in the antibody mixtures of this invention. For example, also 10/90 or 90/10, 20/80 or 80/20 as well as 40/60 or 60/40 may be employed in context of this invention.
  • a particular useful ratio in the antibody mixtures comprised in the formulation of the invention comprises double-glycosylated and mono-glycosylated antibody as defined herein above is a ratio from 40/60 to 45/55.
  • the term "which is free of or to a very low extent" denotes the complete absence of the respective other (glycosylation) isoforms or a presence of another (glycosylated) isoform in a concentration of at the most 10 %, e.g. at the most 5%, e.g. at the most 4%, e.g. at the most 3%, e.g. at the most 2%, e.g. at the most 1%, e.g. at the most 0.5%, e.g. at the most 0.3%, e.g. at the most 0.2%.
  • antibody(ies) is used herein synonymously with the term “antibody molecule(s)” and comprises, in the context of the present invention, antibody molecule(s) like full immunoglobulin molecules, e.g. IgMs, IgDs, IgEs, IgAs or IgGs, like IgGl, IgG2, IgG2b, IgG3 or IgG4 as well as to parts of such immunoglobulin molecules, like Fab- fragments, Fab '-fragments, F(ab)2-fragements, chimeric F(ab)2 or chimeric Fab' fragments, chimeric Fab-fragments or isolated VH- or CDR-regions (said isolated VH- or CDR-regions being, e.g.
  • the term “antibody” also comprises known isoforms and modifications of immunoglobulins, like single-chain antibodies or single chain Fv fragments (scAB/scFv) or bispecific antibody constructs, said isoforms and modifications being characterized as comprising at least one glycosylated VH region as defined herein.
  • a specific example of such an isoform or modification may be a sc (single chain) antibody in the format VH-VL or VL-VH 5 wherein said VH comprises the herein described glycosylation.
  • bispecific scFvs are envisaged, e.g.
  • the present invention also relates to parenteral formulations of Abeta antibodies that comprise "mixtures" of antibodies/antibody molecules. A particular “mixture” of said antibodies is described above, namely a mixture of "mono” and “double”-glycosylated antibodies directed against Abeta.
  • Antibody fragments also comprises such fragments which per se are not able to provide effector functions (ADCC/CDC) but provide this function in a manner according to the invention after being combined with appropriate antibody constant domain(s).
  • the Abeta antibody(ies) that may be comprised in the inventive formulation(s) are, inter alia, recombinantly produced Abeta antibody(ies). These may be produced in a mammalian cell-culture system, e.g. in CHO cells. Such mammalian cell culture systems are particular useful in the preparation of Abeta antibodies or Abeta antibodies/antibody molecules that are glycosylated like the specific herein exemplified Abeta antibody that comprises a N-glycosylation in the variable region.
  • the antibody molecules may be further purified by a sequence of chromatographic and filtration steps e.g. in order to purify the specific glycosylated antibody isoforms as described herein below.
  • the terms “monoclonal antibody” or “monoclonal antibody composition” as used herein refer to a preparation of antibody molecules of a single amino acid composition. Accordingly, the term “human monoclonal antibody” refers to antibodies displaying a single binding specificity which have variable and constant regions derived from human germline immunoglobulin sequences. In one embodiment, the human monoclonal antibodies are produced by a hybridoma which includes a B cell obtained from a transgenic non-human animal, e.g. a transgenic mouse, having a genome comprising a human heavy chain transgene and a light human chain transgene fused to an immortalized cell.
  • a transgenic non-human animal e.g. a transgenic mouse
  • chimeric antibody refers to a monoclonal antibody comprising a variable region, i.e., binding region, from one source or species and at least a portion of a constant region derived from a different source or species, usually prepared by recombinant DNA techniques. Chimeric antibodies comprising a murine variable region and a human constant region are especially preferred. Such murine/human chimeric antibodies are the product of expressed immunoglobulin genes comprising DNA segments encoding murine immunoglobulin variable regions and DNA segments encoding human immunoglobulin constant regions.
  • Other forms of "chimeric antibodies" encompassed by the present invention are those in which the class or subclass has been modified or changed from that of the original antibody.
  • Such “chimeric” antibodies are also referred to as "class-switched antibodies.”
  • Methods for producing chimeric antibodies involve conventional recombinant DNA and gene transfection techniques now well known in the art. See, e.g., Morrison, S. L., et al., Proc. Natl. Acad Sci. USA 81 (1984) 6851-6855; US Patent Nos. 5,202,238 and 5,204,244.
  • the term “humanized antibody” refers to antibodies in which the framework or "complementarity determining regions” (CDR) have been modified to comprise the CDR of an immunoglobulin of different specificity as compared to that of the parent immunoglobulin.
  • CDR complementarity determining regions
  • a murine CDR is grafted into the framework region of a human antibody to prepare the "humanized antibody.” See, e.g., Riechmann, L., et al., Nature 332 (1988) 323-327; and Neuberger, M.S., et al., Nature 314 (1985) 268-270. Particularly preferred CDRs correspond to those representing sequences recognizing the antigens noted above for chimeric and bifunctional antibodies.
  • human antibody is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences.
  • the variable heavy chain is preferably derived from germline sequence DP-50 (GenBank LO6618) and the variable light chain is preferably derived from germline sequence L6 (GenBank XOl 668).
  • the constant regions of the antibody are constant regions of human IgGl type. Such regions can be allotypic and are described by, e.g., Johnson, G., and Wu, T.T., Nucleic Acids Res. 28 (2000) 214-218 and the databases referenced therein and are useful as long as the properties of induction of ADCC and preferably CDC according to the invention are retained.
  • recombinant human antibody is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies isolated from a host cell such as an SP2-0, NSO or CHO cell (like CHO Kl) or from an animal (e.g. a mouse) that is transgenic for human immunoglobulin genes or antibodies expressed using a recombinant expression vector transfected into a host cell.
  • recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences in a rearranged form.
  • the recombinant human antibodies according to the invention have been subjected to in vivo somatic hypermutation.
  • the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo.
  • binding refers to antibody binding to Abeta with an affinity of about 10 "13 to 10 "8 M (K 0 ), preferably of about 10 "13 to 10 *9 M.
  • the "constant domains” are not involved directly in binding the antibody to an antigen but are involved in the effector functions (ADCC, complement binding, and CDC).
  • the constant domain of an antibody according to the invention is of the IgGl type. Human constant domains having these characteristics are described in detail by Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991), and by Bruggemann, M., et al., J. Exp. Med.
  • variable region denotes each of the pair of light and heavy chains which is involved directly in binding the antibody to the antigen.
  • the domains of variable human light and heavy chains have the same general structure and each domain comprises four framework (FR) regions whose sequences are widely conserved, connected by three "hypervariable regions” (or complementarity determining regions, CDRs).
  • the framework regions adopt a ⁇ -sheet conformation and the CDRs may form loops connecting the ⁇ -sheet structure.
  • the CDRs in each chain are held in their three-dimensional structure by the framework regions and form together with the CDRs from the other chain the antigen binding site.
  • the antibody heavy and light chain CDR3 regions play a particularly important role in the binding specificity/affinity of the antibodies according to the invention and therefore provide a further object of the invention.
  • hypervariable region or "antigen-binding portion of an antibody” when used herein refer to the amino acid residues of an antibody which are responsible for antigen- binding.
  • the hypervariable region comprises amino acid residues from the "complementarity determining regions” or "CDRs".
  • “Framework” or "FR” regions are those variable domain regions other than the hypervariable region residues as herein defined. Therefore, the light and heavy chains of an antibody comprise from N- to C-terminus the domains FRl, CDRl, FR2, CDR2, FR3, CDR3, and FR4.
  • CDR3 of the heavy chain is the region which contributes most to antigen binding.
  • CDR and FR regions are determined according to the standard definition of Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and/or those residues from a "hypervariable loop".
  • the formulation of this invention may, inter alia, comprise "stabilizers", "lyoprotectants”, “sugars”, “amino acids”, “polyols”, “antioxidants”, “preservatives”, “surfactants”, “buffers” and/or "tonicity agents".
  • stabilizer denotes a pharmaceutical acceptable excipient, which protects the active pharmaceutical ingredient and/ or the formulation from chemical and / or physical degradation during manufacturing, storage and application. Chemical and physical degradation pathways of protein pharmaceuticals are reviewed by Cleland, J. L., M. F. Powell, et al. (1993). "The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation.” Crit Rev Ther Drug Carrier Syst 10(4): 307-77, Wang, W. (1999). "Instability, stabilization, and formulation of liquid protein pharmaceuticals.” Int J Pharm 185(2): 129-88., Wang, W. (2000).
  • Stabilizers include but are not limited to sugars, amino acids, polyols, surfactants, antioxidants, preservatives, cyclodextrines, e.g.
  • stabilizers can be present in the formulation in an amount of about 10 to about 500 mM, preferably in an amount of about 10 to about 30OmM and more preferably in an amount of about 10OmM to about 30OmM.
  • Lyoprotectant denotes pharmaceutical acceptable excipients, which protects the labile active ingredient (e.g. a protein) against destabilizing conditions during the lyophilisation process, subsequent storage and reconstitution. Lyoprotectants comprise but are not limited to the group consisting of sugars, polyols (such as e.g. sugar alcohols) and amino acids.
  • Preferred lyoprotectants can be selected from the group consisting of: sugars such as sucrose, trehalose, lactose, glucose, mannose, maltose, galactose, fructose, sorbose, and rafFinose neuraminic acid and galactosamine, amino sugars such as glucosamine, N- Methylglucosamine ("Meglumine”), polyols such as mannitol, and amino acids such as arginine. Lyoprotectants are generally used in an amount of about 10 to 50OmM, preferably in an amount of about 10 to about 30OmM and more preferably in an amount of about 100 to about 30OmM.
  • sugars such as sucrose, trehalose, lactose, glucose, mannose, maltose, galactose, fructose, sorbose, and rafFinose neuraminic acid and galactosamine
  • amino sugars such as gluco
  • sugar denotes a pharmaceutically acceptable carbohydrate used generally in an amount of about 10 mM to about 500 mM, preferably in an amount of about 10 to about 30OmM and more preferably in an amount of about 100 to about 30OmM.
  • Suitable sugars comprise but are not limited to trehalose, sucrose, lactose, glucose, mannose, maltose, galactose, fructose, sorbose, raffinose, glucosamine, N-Methylglucosamine (so- called "Meglumine”), galactosamine and neuraminic acid.
  • Preferred sugars are sucrose and trehalose and more preferably sucrose.
  • amino acid as used herein in the context of the pharmaceutical parenteral formulation denotes a pharmaceutical acceptable organic molecule possessing an amino moiety located at ⁇ -position to a carboxylic group.
  • Amino acids comprise but not limited to arginine, glycine, ornithine, lysine, histidine, glutamic acid, aspartic acid, isoleucine, leucine, alanine, phenylalanine, tyrosine, tryptophan, methionine, serine, proline and combinations thereof.
  • Amino acids are generally used in an amount of about 10 to 50OmM, preferably in an amount of about 10 to about 30OmM and more preferably in an amount of about 100 to about 30OmM.
  • polyols denotes pharmaceutically acceptable alcohols with more than one hydroxy group.
  • Polyols can be used in an amount of about 10 mM to about 50OmM, preferably in an amount of about 10 to about 300 and more preferably in an amount of about 100 to about 30OmM.
  • Suitable polyols comprise to but are not limited to mannitol, sorbitol, glycerine, dextran, glycerol, arabitol, propylene glycol, polyethylene glycol, and combinations thereof.
  • antioxidant denotes pharmaceutically acceptable excipients, which prevent oxidation of the active pharmaceutical ingredient.
  • Antioxidants can be used in an amount of about 1 to about 10OmM, preferably in an amount of about 5 to about 5OmM and more preferably in an amount of about 5 to about 2OmM.
  • Antioxidants comprise but are not limited to ascorbic acid, glutathione, cysteine, methionine, citric acid, EDTA, and combinations thereof.
  • preservative denotes pharmaceutically acceptable excipients, which prevent the growth of microorganism in the formulation.
  • a preservative to a multi-dose formulation protects the formulation against microbial contamination.
  • Preservatives are generally used in an amount of about 0.001 to about 2 %(w/v).
  • Preservatives comprise but are not limited to ethanol, benzyl alcohol, phenol, m-cresol, p- chlor-m-cresol, methyl or propyl parabens, benzalkonium chloride, and combinations thereof.
  • surfactant denotes a pharmaceutically acceptable surfactant.
  • the amount of surfactant is described a percentage expressed in weight/volume percent (w/v %).
  • Suitable pharmaceutically acceptable surfactants comprise but are not limited to the group of polyoxyethylensorbitan fatty acid esters (T ween), polyoxy ethylene alkyl ethers (Brij), alkylphenylpolyoxyethylene ethers (Triton-X), polyoxyethylene-polyoxypropylene copolymer (Poloxamer, Pluronic)., and sodium dodecyl sulphate (SDS).
  • Preferred polyoxyethylenesorbitan-fatty acid esters are polysorbate 20,(sold under the trademark Tween 20TM) and polysorbate 80 (sold under the trademark Tween 80TM).
  • Preferred polyethylene-polypropylene copolymers are those sold under the names Pluronic® F68 or Poloxamer 188TM.
  • Preferred Polyoxyethylene alkyl ethers are those sold under the trademark BrijTM.
  • Preferred alkylphenolpolyoxyethylene ethers are sold under the tradename Triton-X.
  • polysorbate 20 Tween 20TM
  • polysorbate 80 T ween 80TM
  • concentration range of about 0.001 to about 1%, preferably of about 0.005 to about 0.1% and still preferably about 0.01% to about 0.04%w/v.
  • buffer denotes a pharmaceutically acceptable excipient, which stabilizes the pH of a pharmaceutical preparation.
  • Suitable buffers are well known in the art and can be found in the literature.
  • Preferred pharmaceutically acceptable buffers comprise but are not limited to histidine-buffers, citrate-buffers, succinate-buffers and phosphate-buffers.
  • Still preferred buffers comprise L-histidine or mixtures of L-histidine and L-histidine hydrochloride with pH adjustment with an acid or a base known in the art.
  • the abovementioned histidine-buffers are generally used in an amount of about ImM to about 100 mM, preferably of about 5 mM to about 50 mM and still more preferably of about 10-20 mM.
  • the pH can be adjusted at a value comprising about 4.0 to about 7.0 and preferably about 5.0 to about 6.0 and still preferably about 5.5 with an acid or a base known in the art, e.g., hydrochloric acid, acetic acid, phosphoric acid, sulfuric acid and citric acid, sodium hydroxide and potassium hydroxide
  • tonicity agents denotes pharmaceutically acceptable tonicity agents.
  • Tonicity agents are used to modulate the tonicity of the formulation.
  • the formulation can be hypotonic, isotonic or hypertonic. Isotonicity is generally relates to the osmotic pressure relative of a solution usually relative to that of human blood serum.
  • the formulation according to the invention can be hypotonic, isotonic or hypertonic but will preferably be isotonic. In a concern for clarity it is once more emphasized that an isotonic formulation is liquid or liquid reconstituted from a solid form, e.g.
  • Suitable isotonicity agents comprise but are not limited to sodium chloride, potassium chloride, glycerin and any component from the group of amino acids, sugars, in particular glucose as defined herein as well as combinations thereof. Tonicity agents are used in an amount of about 5 mM to about 500 mM.
  • liquid as used herein in connection with the formulation according to the invention denotes a formulation which is liquid at a temperature of at least about 2 to about 8 0 C under standard pressure.
  • lyophilizate as used herein in connection with the formulation according to the invention denotes a formulation which is manufactured by freeze-drying methods known in the art per se.
  • the solvent e.g. water
  • the lyophilizate has usually a residual moisture of about 0.1 to 5% (w/w) and is present as a powder or a physical stable cake.
  • the lyophilizate is characterized by a fast dissolution after addition of a reconstirution medium.
  • the term "reconstituted formulation” as used herein in connection with the formulation according to the invention denotes a formulation which is lyophilized and re-dissolved by addition of reconstirution medium.
  • the reconstirution medium comprises but is not limited to water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solutions (e.g. 0.9% (w/v) NaCl), glucose solutions (e.g. 5% glucose), surfactant containing solutions (e.g. 0.01% polysorbate 20), a pH -buffered solution (e.g. phosphate-buffered solutions) and combinations thereof.
  • WFI water for injection
  • BWFI bacteriostatic water for injection
  • sodium chloride solutions e.g. 0.9% (w/v) NaCl
  • glucose solutions e.g. 5% glucose
  • surfactant containing solutions e.g. 0.01% polysorbate 20
  • a pH -buffered solution e.g. phosphate-buffered solutions
  • stable formulation denotes a formulation, which preserves its physical and chemical integrity during manufacturing, storage and application.
  • Various analytical techniques for evaluating protein stability are available and reviewed in Reubsaet, J. L., J. H. Beijnen, et al. (1998). "Analytical techniques used to study the degradation of proteins and peptides: chemical instability”. J Pharm Biomed Anal 17(6-7): 955-78 and Wang, W. (1999). "Instability, stabilization, and formulation of liquid protein pharmaceuticals.” Int J Pharm 185(2): 129-88.
  • Stability can be evaluated by storage at selected climate conditions for a selected time period, by applying mechanical stress such as shaking at a selected shaking frequency for a selected time period, by irradiation with a selected light intensity for a selected period of time, or by repetitive freezing and thawing at selected temperatures.
  • pharmaceutically acceptable as used herein in connection with the formulation according to the invention denotes a formulation which is in compliance with the current international regulatory requirements for pharmaceuticals.
  • a pharmaceutical acceptable formulation contains excipients which are generally recognized for the anticipated route of application and concentration range as safe. In addition, it should provide sufficient stability during manufacturing, storage and application. Especially a formulation for a parenteral route of application should fulfill the requirements isotonicity and euhydric pH in comparison to the composition of human blood.
  • the invention relates to a stable pharmaceutical parenteral Abeta antibody formulation comprising:
  • the Abeta antibody concentration ranges from about 1 to about 250 mg/mL, preferably from about 50 mg/mL to about 200 mg/mL and more preferably from about 150 mg/mL to about 200 mg/mL.
  • concentrations as indicated herein relate to the concentration in a liquid or in a liquid that is accurately reconstituted from a solid form. Accordingly, the lyophilized formulations as described herein can be reconstituted from a lyophilizate in such way that the resulting reconstituted formula comprises the respective constituents in the concentrations described herein.
  • the stable lyophilizates as described herein may also be reconstituted using such an amount of reconstitution medium that the resulting reconstituted formulation is either more concentrated or less concentrated.
  • the lyophilizate of "Formulation A" as described herein in Table 2 may be reconstituted in such way that the resulting reconstituted formulation is further diluted to comprise e.g. 20mg/mL Abeta antibody, 5.3mM L-histidine, 66.7mM Sucrose and 0.01 1% polysorbate 20; see Formulation R of Table 2.
  • the formulation according to the invention can be in a liquid form, a lyophilized form or in a liquid form reconstituted from a lyophilized form.
  • the formulation of the invention in a lyophilized form or in a liquid from reconstituted from a lyophilized form, it can comprise at least one lyoprotectant as stabilizer.
  • the formulation according to the invention can be administered by intravenous (i.v.), subcutaneous (s.c.) or any other parenteral administration means such as those known in the pharmaceutical art.
  • the formulation according to the invention is preferably administered by subcutaneous ways.
  • the formulation according to the invention can be prepared by methods known in the art, such as ultraf ⁇ ltration-diafiltration, dialysis, addition and mixing, lyophilisation, reconstitution, and combinations thereof. Examples of preparations of formulations according to the invention can be found hereinafter.
  • the Abeta antibody comprised in the pharmaceutical parenteral formulation of the present invention may comprise or have the variable region as defined in SEQ ID NO: 1 : QVELVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINASGT
  • MMALHNHYTQKSLSLSPGK (SEQ ID NO: 1) 3 underlined: CHl italics: hinge underlined twice: CH2 dotted underlined;, CH3 bold N: N-linked glycosylation sites
  • the exemplified Abeta antibody comprising SEQ ID NO: 1 as described herein may also comprise a light chain, said light chain may comprise or have the following amino acid sequence: D ⁇ VLTQSPATLSLSPGERATLSCRASQSVSSSYLA WYQQKPGQ APRLLIYGASSRATG VP ARFSGSGSGTDFTLTISSLEPEDFATYYCLQIYNMPITFGQGTKVEIKRTV AAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 2)
  • Abeta antibody A relates to the exemplified Abeta antibody comprising a heavy chain as defined in SEQ ID NO: 1 and a light chain as defined in SEQ ID NO: 2.
  • the term "mono-glycosylated antibody(ies)”, as used herein, relates to antibody molecules comprising an N-glycosylation in one (VH)-region of an individual antibody molecule, e.g. of an immunoglobulin, e.g. an IgG, e.g. of an IgGl.
  • said "mono- glycosylated form” comprises a glycosylation on one variable region of the heavy chain e.g. at position asparagine "Asn 52" of the herein described "Abeta antibody A".
  • This "mono- glycosylated IgGl -form or mono-glycosylated isoform” may also comprise, as illustrated herein, the glycosylation in the well conserved glycosylation site in the Fc-part, for example asparagine Asn 306 in the non-variable Fc-part of the herein exemplified "Abeta antibody A”.
  • double-glycosylated antibody(ies) in the meaning of this invention comprises the herein defined glycosylation on both variable regions of the heavy chain (VH)- region.
  • this "double glycosylated form” comprises a glycosylation on the variable region of both heavy chains, e.g. at position asparagine Asn 52 of the herein exemplified “Abeta antibody A”.
  • This "double-glycosylated IgGl -form or double-glycosylated isoform” may also comprise, as illustrated herein, the glycosylation in the well conserved glycosylation site in the non-variable/constant Fc-part, in particular on position 306 of the exemplified "Abeta antibody A”.
  • Appended figure 1 illustrates corresponding antibody molecules.
  • Antibodies devoid of such a post-translational modification in the variable region e.g. in both variable regions of the heavy chain (both (VH)-regions) are, in context of this invention considered as a "non-glycosylated form", comprising no glycosylation in the variable region of the heavy chain.
  • this "non-glycosylated form” may nevertheless comprise (a) glycosylation(s) in the constant region (C-region) of the antibody, for example, and most commonly at the well conserved glycosylation site of the Fc-part, in particular the asparagine (Asn) 306 in the non- variable/constant Fc-part as defined herein; see also SEQ ID NO: 1.
  • the pharmaceutical parenteral formulations of the invention may comprise the exemplary "Abeta antibody A" as defined herein above and as illustrated in the appended examples. Accordingly, said pharmaceutical parenteral formulations comprising Abeta antibody A may comprise mono-glycosylated Abeta antibody A or double-glycosylated Abeta antibody A or non-glycosylated Abeta antibody A or mixtures thereof as defined above.
  • Purification of glycosylation isoforms of recombinantly expressed Abeta antibody molecules may comprise the steps of:
  • the purification protocol may comprise further steps, like further concentration steps, e.g. diafiltration or analytical steps, e.g. involving analytical columns. It is also envisaged and feasible that particular certain steps are repeated (e.g. two ion exchange chromatography steps may be carried out) or that certain steps (e.g. size exclusion chromatography) may be omitted.
  • Protein A is a group specific ligand which binds to the Fc region of most IgGl isotypes. It is synthesized by some strains of Staphylococcus aureus and can be isolated therefrom and coupled to chromatographic beads. Several types of gel preparations are available commercially.
  • An example for a protein A column which may be used is a MabSelect (Trademark) column. Ideally the column is equilibrated with 25 mM Tris/HCl, 25 mM NaCl, 5 mM EDTA, the cell culture supernatant is loaded onto the column, the column is washed with 1 M Tris/HCl pH 7,2 and the antibody is eluted at pH 3.2 using 100 mM acetic acid.
  • Cation-exchange chromatography exploits interactions between positively charged groups in a stationary phase and the sample which is in the mobile phase.
  • a weak cation exchanger e.g. CM Toyopearl 650®
  • the following chromatographic steps are performed: After preequilibration with 100 mM acetic acid pH 4, loading of Protein A eluate and washing with 100 mM acetic acid pH 4 the antibody is eluted and fractionated by applying steps of 250 mM sodium acetate (pH 7.8-8.5) and 500 mM sodium acetate (pH 7.8- 8.5).
  • the first step a mixture of double-glycosylated isoform fraction and mono- glycosylated isoform fraction are normally eluted
  • using the second step the non-glycosylated isoform fraction is normally eluted.
  • the antibody can be eluted by salt steps: After equilibration of the column with 50 mM acetic acid pH 5.0, loading the Protein A eluate with pH 4 the first elution step using 50 mM acetic acid and 210 mM sodium chloride is performed. Then a second elution step of 50 mM acetic acid and 350 mM sodium chloride is applied.
  • a first salt step a mixture of the double-glycosylated isoform fraction and mono-glycosylated isoform fraction are normally eluted
  • the second salt step the non-glycosylated isoform is normally eluted.
  • the antibody may also be eluted from a strong cation exchanger column (e.g. SP-Sepharose®) by a salt gradient: After preequilibration, loading and washing the column at pH 4.5 a salt gradient is applied from 50 mM MES pH 5.8 to 50 mM MES /1 M sodium chloride pH 5.8.
  • a salt gradient is applied from 50 mM MES pH 5.8 to 50 mM MES /1 M sodium chloride pH 5.8.
  • the double-glycosylated isoform, mono-glycosylated isoform and non-glycosylated isoform fractions are normally eluted separately.
  • double-glycosylated isoform fraction and mono-glycosylated isoform fraction may be pooled to result in the product pool and/or a desired antibody mixture.
  • Further purification of the mixture of double- and mono-glycosylated antibody molecules, e.g. immunoglobulins, may be performed by size exclusion chromatography.
  • An example of a useful column is a Superdex 200® column.
  • Examples of running buffers include histidine/sodium chloride, e.g. 10 mM histidine/125 mM sodium chloride/pH 6, and phosphate buffered saline (PBS).
  • Anion exchange chromatography in the flow through mode followed by a concentration/ diafiltration is an alternative purification step.
  • Q Sepharose® is an example for a resin for the anion exchange step.
  • the eluate from the SP chromatography may be threefold diluted with 37,5 mM Tris/HCl pH 7.9 and passed over a Q-Sepharose column pre-equilibrated with 25 mM Tris/83 mM sodium acetate.
  • the flow through is collected, adjusted to pH 5.5 and concentrated by ultrafiltration using e.g. a Hydrosart 30 kD® membrane.
  • the concentrate may be diafiltrated against for example 10 volumes of 20 mM histidine/HCl pH 5.5.
  • antibody isoforms may also comprise (a) further glycosylation(s) in the constant/non- variable part of the antibody molecules, e.g. in the Fc-part of an IgG, e.g. in the Fc-part in an IgGl.
  • Said glycosylation in the Fc-part relates to a well conserved glycosylation, being characterized in located on position Asn306 of the heavy chain, e.g., in accordance with the herein defined SEQ ID NO: 1.
  • the IgG-Fc region of the antibodies comprised in the formulations of this invention may be a homodimer comprised of inter-chain disulphide bonded hinge regions, glycosylated CH2 domains, bearing N-linked oligosaccharide at asparagine 306 (Asn-306) of the CH2 and non-covalently paired CH3 domains.
  • the oligosaccharide of the glycosylation at Asn-306 is of the complex biantennary type and may comprise a core heptasaccharide structure with variable addition of outer arm sugars.
  • the oligosaccharide influences or determines Fc structure and function (Jefferis (1998) Immunol Rev. 163, 50-76). Effector functions, numbering particular specific IgG-Fc/effector ligand interactions have been discussed (Jefferis (2002) Immunol Lett. 82(1-2), 57-65 and Krapp (2003) J MoI Biol. 325(5), 979-89). This conserved Fc-position Asn-306 corresponds to "Asn-297" in the Kabat-system (Kabat (1991) Sequences of Proteins of Immunological Interest, 5th Ed., Public Health Service, National Institutes of Health, Bethesda MD.)
  • the formulation of the invention is a liquid or lyophilized formulation comprising:
  • the formulation according to the invention also comprises a lyophilized formulation comprising:
  • the formulation according to the invention also comprises a liquid formulation comprising:
  • the formulation according to the invention also comprises a lyophilized formulation comprising:
  • the formulation according to the invention also comprises a lyophilized formulation comprising:
  • the formulation according to the invention also comprises a liquid formulation comprising:
  • the formulation according to the invention also comprises a lyophilized formulation comprising:
  • the formulation according to the invention also comprises a liquid formulation comprising:
  • the formulation according to the invention also comprises a liquid formulation comprising:
  • the formulation according to the invention also comprises a liquid formulation comprising:
  • the formulation according to the invention also comprises a lyophilized formulation comprising:
  • the formulation according to the invention also comprises a lyophilized formulation comprising:
  • FIG. 1 Scheme of double-, mono- and non-glycosylated antibody molecules (immunoglobulins).
  • Figure 2 Content of monomer as determined by size-exclusion chromatography of Abeta antibody A formulations after start and incubation at 5°C, 25°C/60%rh and 40°C/75%rh for up to 6 months.
  • Antibody preparations are freeze-dried and reconstituted to nominal concentration of 75mg/mL.
  • Antibody preparations K, L and N are formulated at 75mg/mL, whereas preparations O, P and Q are formulated at 150mg/mL.
  • Liquid and lyophilized drug product formulations for subcutaneous administration according to the invention were developed as follows:
  • Abeta antibody comprising a heavy chain as defined in SEQ ID NO: 1 and a light chain as defined in SEQ ID NO: 2 (“Abeta antibody A" in the context of the present invention) was prepared and obtained as described in WO 03/070760 and was concentrated by ultrafiltration to a concentration of approx. 40 to about 200 mg/mL in a 20 mM histidine buffer at a pH of approx. 5.5. The concentrated solution was then diluted with the formulation buffer (containing sugar (respectively salt or polyol), surfactant and buffer at a pH of approx. pH 5.5) resulting the anticipated antibody concentration of approx.
  • the formulation buffer containing sugar (respectively salt or polyol), surfactant and buffer at a pH of approx. pH 5.5
  • 7.5mg/mL, 37.5 mg/mL, 75 mg/mL or 150mg/mL formulated in the final bulk composition e.g. 10 mM L-histidine, 125 mM sucrose, 0.02% Tween 20, at pH 5.5.
  • Abeta antibody A was buffer-exchanged against a diafiltration buffer containing the anticipated buffer and sugar composition and concentrated to an antibody concentration equal or higher than the final concentration of approx. 37.5mg/mL.
  • the surfactant was added after completion of the ultrafiltration operation as a 100 to 200-fold stock solution to the antibody solution.
  • the concentrated antibody solution was adjusted with a formulation buffer containing the identical excipient composition to the final Abeta antibody A concentration of approx. 37.5 mg/mL.
  • the lyophilization process used for this study included the cooling of the formulation from room temperature to approx 5°C (pre-cooling) and a freezing step to -40°C at a plate cooling rate of approx. l°C/min, followed by a holding step at -4O 0 C for about 2 hours .
  • the first drying step was performed at a plate temperature of approx. -25°C and a chamber pressure of approx. 80 ⁇ bar for about 62 hours.
  • the second drying step started with a temperature ramp of 0.2°C / min from -25°C to 25 0 C, followed by a holding step at 25°C for at least 5 hours at a chamber pressure of approx. 80 ⁇ bar (the applied drying schedule is presented in Table 1.)
  • Lyophilization was carried out in an Usifroid SMH-90 LN2 freeze-dryer (Usifroid, Maurepas, France). All lyophilized cakes in this study had a residual water content of about 0.1 to 1.0% as determined by Karl-Fischer method. The freeze-dried samples were incubated at different temperatures for different intervals of time.
  • the lyophilized formulations were reconstituted to a final volume of 1.2 mL with water for injection (WFI) yielding an isotonic formulation with an antibody concentration of approx. 75 mg/mL and a viscosity of less than 3 mPa-s.
  • the reconstitution time of the freeze- dried cakes was about 2 to 4min. Analysis of the reconstituted samples was either performed immediately after reconstitution, or after a 24 hour incubation period of the reconstituted liquid sample at 25 0 C.
  • the samples were analyzed by 1) UV spectrophotometry, 2) determination of the reconstitution time, 3) Size Exclusion Chromatography (SEC) and 4) method of nephelometry to determine the turbidity of the solution.
  • Size Exclusion Chromatography was used to detect soluble high molecular weight species (aggregates) and low molecular weight hydrolysis products (LMW) in the formulations.
  • the method was performed on a Merck Hitachi 7000 HPLC instrument equipped with a Tosohaas TSK G3000 SWXL column. Intact monomer, aggregates and hydrolysis products are separated by an isocratic elution profile, using 0.2M K 2 HPO 4 / 0.25M KCL, pH 7.0 as mobile phase, and were detected at a wavelength of 280nm.
  • UV spectroscopy used for determination of protein content, was performed on a Varian Cary Bio UV spectrophotometer at 280 nm. Neat protein samples were diluted to approx. 0.5 mg/mL with 20 mM L-histidine, pH 5.5. The protein concentration was calculated according equation 1.
  • the protein concentration was measured with a precision of ⁇ 10%.
  • the UV light absorption at 280 nm was corrected for light scattering at 320 nm and multiplied with the dilution factor, which was determined from the weighed masses and densities of the neat sample and the dilution buffer.
  • the numerator was divided by the product of the cuvette's path length d and the extinction coefficient ⁇ .
  • Clarity and the degree of opalescence were measured as Formazin Turbidity Units (FTU) by the method of nephelometry.
  • the neat sample was transferred into a l l mm diameter clear-glass tube and placed into a HACH 2100 AN turbidimeter.

Abstract

The present invention relates to a stable pharmaceutical parenteral formulation of an antibody, antibody molecule, a mixture of antibodies and/or a mixture of antibody molecules against the amyloid-beta peptide (Abeta) and a process for the preparation. Furthermore, corresponding uses are described.

Description

Abeta antibody parenteral formulation
The present invention relates to a stable pharmaceutical parenteral formulation of an antibody, antibody molecule, a mixture of antibodies and/or a mixture of antibody molecules against the amyloid-beta peptide (Abeta) and a process for the preparation thereof. Furthermore, corresponding uses are described.
In a first aspect, the invention relates to a stable pharmaceutical parenteral Abeta antibody pharmaceutical formulation comprising: about 1 to about 250 mg/mL Abeta antibody; - about 0.001 to about 1% of at least one surfactant; about 1 to about 100 mM of a buffer; optionally about 10 to about 500 mM of a stabilizer and/or about 5 to about 500 mM of a tonicity agent; at a pH of about 4.0 to about 7.0.
In particular, the present invention relates to an Abeta antibody formulation wherein the comprised Abeta antibodies (or mixtures thereof) are capable of specifically binding the amyloid-beta peptide. Antibodies that specifically bind Abeta are known in the art. Specific examples of Abeta antibody that can be used in the formulation according to the invention have been described in the published PCT patent application WO 03/070760 and especially in the claims, the content of which is incorporated herein by reference.
The amyloid-beta peptide, which is also termed "amyloid β", "Aβ", "Aβ4" or "β-A4" and, in particular in context of this invention "Abeta", is a main component of the extracellular neuritic plaques that are associated with amyloidogenic diseases such as Alzheimer's disease; see Selkoe (1994), Ann. Rev. Cell Biol. 10, 373-403, Koo (1999), PNAS Vol. 96, pp. 9989-9990, US 4,666,829 or Glenner (1984), BBRC 12, 1131. This amyloid β is derived from "Alzheimer precursor protein/β-amyloid precursor protein" (APP). APPs are integral membrane glycoproteins (see Sisodia (1992), PNAS Vol. 89, pp. 6075) and are endoproteolytically cleaved within the Abeta sequence by a plasma membrane protease, α-secretase (see Sisodia (1992), loc. cit.). Furthermore, further secretase activity, in particular β-secretase and γ-secretase activity leads to the extracellular release of amyloid-β (Aβ) comprising either 39 amino acids (Aβ39), 40 amino acids (Aβ40), 42 amino acids (Aβ42) or 43 amino acids (Aβ43); see Sinha (1999), PNAS 96, 11094-1053; Price (1998), Science 282, 1078 to 1083; WO 00/72880 or Hardy (1997), TINS 20, 154.
Aβ has several naturally occurring forms, whereby the human forms are referred to as the above mentioned Aβ39, Aβ40, Aβ41, Aβ42 and Aβ43. The most prominent form, Aβ42, has the amino acid sequence (starting from the N-terminus): DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA (SEQ ID NO: 3). In Aβ41, Aβ40, Aβ39, the C-terminal amino acids A, LA and VIA are missing, respectively. In the Aβ43-form an additional threonine residue is comprised at the C-terminus of the above depicted sequence (SEQ ID NO: 3).
Antibody molecules, as part of the group of protein pharmaceuticals, are very susceptible to physical and chemical degradation, such as denaturation and aggregation, deamidation, oxidation and hydrolysis. Protein stability is influenced by the characteristics of the protein itself, e.g. the amino acid sequence, and by external influences, such as temperature, solvent pH, excipients, interfaces, or shear rates. So, it is important to define the optimal formulation conditions to protect the protein against degradation reactions during manufacturing, storage and administration. (Manning, M. C, K. Patel, et al. (1989). "Stability of protein pharmaceuticals." Pharm Res 6(11): 903-18., Zheng, J. Y. and L. J. Janis (2005). "Influence of pH, buffer species, and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298." Int_J_Pharm.)
Administration of antibodies via subcutaneous or intramuscular route requires high protein concentration in the final formulation due to the often required high doses and the limited administration volumes. (Shire, S. J., Z. Shahrokh, et al. (2004). "Challenges in the development of high protein concentration formulations." J Pharm Sci 93(6): 1390-402., Roskos, L. K., C. G. Davis, et al. (2004). "The clinical pharmacology of therapeutic monoclonal antibodies." Drug Development Research 61(3): 108-120.) The large-scale manufacturing of high protein concentration can be achieved by ultrafiltration processes, drying process, such as lyophilisation or spray-drying, and precipitation processes. (Shire, S. J., Z. Shahrokh, et al. (2004). "Challenges in the development of high protein concentration formulations." J Pharm Sci 93(6): 1390-402.) Andya et al. (US patent 6,267,958, US patent 6,85,940) describe a stable lyophilized formulation of an antibody, which is reconstituted with a suitable diluent volume to achieve the required concentration. The formulation comprises a lyoprotectant, a buffer and a surfactant.
Liu et al. (Liu, J., M. D. Nguyen, et al. (2005). "Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution." J Pharm Sci 94(9): 1928-40.) examined the viscosity behavior of high concentration antibody formulations. Three monoclonal antibodies, constructed from the identical IgGl framework, were examined for their self-association at high protein concentration. The three antibodies demonstrated no consistent viscosity-profile and showed significant differences in their self- association behavior.
One object of the present invention is to provide a formulation of an Abeta antibody or of mixtures of such antibodies, which is/are concentrated to the required concentration by reconstitution of a lyophilized formulation with a suitable volume or by removing the solvent by an ultrafiltration process. The formulation demonstrates sufficient stability during manufacturing, storage and administration. As demonstrated by Liu et al., antibodies show an unpredictable viscosity-concentration profile. (Liu, J., M. D. Nguyen, et al. (2005). "Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution." J Pharm Sci 94(9): 1928-40.) In comparison to the patents US 6,267,958 and US 6,685,940 the presented formulation provides equal or better stability of an Abeta human antibody during storage and has a viscosity, which is suitable for the subcutaneous or intramuscular administration route.
Examples of Abeta antibodies that are useful in the present invention are immunoglobulin molecules, e.g. IgG molecules. IgGs are characterized in comprising two heavy and two light chains (illustrated e.g. in figure 1) and these molecules comprise two antigen binding sites. Said antigen binding sites comprise "variable regions" consisting of parts of the heavy chains (VH) and parts of the light chains (VL). The antigen-binding sites are formed by the juxtaposition of the VH and VL domains. For general information on antibody molecules or immunoglobulin molecules see also common textbooks, like Abbas "Cellular and Molecular Immunology", W.B. Sounders Company (2003). In one embodiment, the parenteral formulation of the present invention comprises Abeta antibody (or mixture of such antibodies) in which in at least one of the variable regions in the heavy chain of said antibodies comprises a N-glycosylation. The glycosylated asparagine (Asn) in the variable region of the heavy chain (VH) may be in the complementarity determining region 2 (CDR2 region), said glycosylated asparagine (Asn) may be on position 52 in the variable region of the heavy chain (VH) as shown in SEQ ID NO: 1.
The term "mono-glycosylated antibody" relates to an antibody molecule comprising an N-glycosylation in one (VH)-region of an individual antibody molecule"; see also figure 1. The term "double-glycosylation antibody" defines an antibody molecule which is N- glycosylated on both variable regions of the heavy chain" (figure 1). Antibody molecules which lack a N-glycosylation on both heavy chain (VH)-domains are named "non- glycosylated antibodies" (figure 1). The mono-glycosylated antibody, the double- glycosylated antibody and the non-glycosylated antibody may comprise the identical amino acid sequences or different amino acid sequences.
The mono-glycosylated antibody and the double-glycosylated antibody are herein referred to as "glycosylated antibody isoforms". A purified antibody molecule characterized in that at least one antigen binding site comprises a glycosylation in the variable region of the heavy chain (VH) is a mono-glycosylated antibody which is free of or to a very low extent associated with an isoform selected from a double-glycosylated antibody and a non- glycosylated antibody, i.e. a "purified mono-glycosylated antibody". A double-glycosylated antibody in context of this invention is free of or to a very low extent associated with an isoform selected from a mono-glycosylated antibody and a non-glycosylated antibody, i.e. a "purified double-glycosylated antibody".
The formulations according to this invention may contain mono-glycosylated or double-glycosylated or non-glycosylated antibodies, or specifically defined mixtures thereof. The antibody mixtures or antibody pools provided herein may comprise 50% mono- glycosylated and 50% double-glycosylated antibodies as defined herein. However, also envisaged are the ratios of 30/70 to 70/30. Yet, the person skilled in the art is aware that also other ratios are envisaged in the antibody mixtures of this invention. For example, also 10/90 or 90/10, 20/80 or 80/20 as well as 40/60 or 60/40 may be employed in context of this invention. A particular useful ratio in the antibody mixtures comprised in the formulation of the invention comprises double-glycosylated and mono-glycosylated antibody as defined herein above is a ratio from 40/60 to 45/55.
The term "which is free of or to a very low extent" denotes the complete absence of the respective other (glycosylation) isoforms or a presence of another (glycosylated) isoform in a concentration of at the most 10 %, e.g. at the most 5%, e.g. at the most 4%, e.g. at the most 3%, e.g. at the most 2%, e.g. at the most 1%, e.g. at the most 0.5%, e.g. at the most 0.3%, e.g. at the most 0.2%.
The term "antibody(ies)" is used herein synonymously with the term "antibody molecule(s)" and comprises, in the context of the present invention, antibody molecule(s) like full immunoglobulin molecules, e.g. IgMs, IgDs, IgEs, IgAs or IgGs, like IgGl, IgG2, IgG2b, IgG3 or IgG4 as well as to parts of such immunoglobulin molecules, like Fab- fragments, Fab '-fragments, F(ab)2-fragements, chimeric F(ab)2 or chimeric Fab' fragments, chimeric Fab-fragments or isolated VH- or CDR-regions (said isolated VH- or CDR-regions being, e.g. to be integrated or engineered in corresponding "framework(s)") Accordingly, the term "antibody" also comprises known isoforms and modifications of immunoglobulins, like single-chain antibodies or single chain Fv fragments (scAB/scFv) or bispecific antibody constructs, said isoforms and modifications being characterized as comprising at least one glycosylated VH region as defined herein. A specific example of such an isoform or modification may be a sc (single chain) antibody in the format VH-VL or VL-VH5 wherein said VH comprises the herein described glycosylation. Also bispecific scFvs are envisaged, e.g. in the format VH-VL-VH-VL, VL-VH-VH-VL, VH-VL-VL-VH. Also comprised in the term "antibody" are diabodies and molecules that comprise an antibody Fc domain as a vehicle attached to at least one antigen binding moiety/peptide, e.g. peptibodies as described in WO 00/24782. It is evident from the above that the present invention also relates to parenteral formulations of Abeta antibodies that comprise "mixtures" of antibodies/antibody molecules. A particular "mixture" of said antibodies is described above, namely a mixture of "mono" and "double"-glycosylated antibodies directed against Abeta.
"Antibody fragments" also comprises such fragments which per se are not able to provide effector functions (ADCC/CDC) but provide this function in a manner according to the invention after being combined with appropriate antibody constant domain(s). The Abeta antibody(ies) that may be comprised in the inventive formulation(s) are, inter alia, recombinantly produced Abeta antibody(ies). These may be produced in a mammalian cell-culture system, e.g. in CHO cells. Such mammalian cell culture systems are particular useful in the preparation of Abeta antibodies or Abeta antibodies/antibody molecules that are glycosylated like the specific herein exemplified Abeta antibody that comprises a N-glycosylation in the variable region. The antibody molecules may be further purified by a sequence of chromatographic and filtration steps e.g. in order to purify the specific glycosylated antibody isoforms as described herein below.
The terms "monoclonal antibody" or "monoclonal antibody composition" as used herein refer to a preparation of antibody molecules of a single amino acid composition. Accordingly, the term "human monoclonal antibody" refers to antibodies displaying a single binding specificity which have variable and constant regions derived from human germline immunoglobulin sequences. In one embodiment, the human monoclonal antibodies are produced by a hybridoma which includes a B cell obtained from a transgenic non-human animal, e.g. a transgenic mouse, having a genome comprising a human heavy chain transgene and a light human chain transgene fused to an immortalized cell.
The term "chimeric antibody" refers to a monoclonal antibody comprising a variable region, i.e., binding region, from one source or species and at least a portion of a constant region derived from a different source or species, usually prepared by recombinant DNA techniques. Chimeric antibodies comprising a murine variable region and a human constant region are especially preferred. Such murine/human chimeric antibodies are the product of expressed immunoglobulin genes comprising DNA segments encoding murine immunoglobulin variable regions and DNA segments encoding human immunoglobulin constant regions. Other forms of "chimeric antibodies" encompassed by the present invention are those in which the class or subclass has been modified or changed from that of the original antibody. Such "chimeric" antibodies are also referred to as "class-switched antibodies." Methods for producing chimeric antibodies involve conventional recombinant DNA and gene transfection techniques now well known in the art. See, e.g., Morrison, S. L., et al., Proc. Natl. Acad Sci. USA 81 (1984) 6851-6855; US Patent Nos. 5,202,238 and 5,204,244. The term "humanized antibody" refers to antibodies in which the framework or "complementarity determining regions" (CDR) have been modified to comprise the CDR of an immunoglobulin of different specificity as compared to that of the parent immunoglobulin. In a preferred embodiment, a murine CDR is grafted into the framework region of a human antibody to prepare the "humanized antibody." See, e.g., Riechmann, L., et al., Nature 332 (1988) 323-327; and Neuberger, M.S., et al., Nature 314 (1985) 268-270. Particularly preferred CDRs correspond to those representing sequences recognizing the antigens noted above for chimeric and bifunctional antibodies.
The term "human antibody", as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The variable heavy chain is preferably derived from germline sequence DP-50 (GenBank LO6618) and the variable light chain is preferably derived from germline sequence L6 (GenBank XOl 668). The constant regions of the antibody are constant regions of human IgGl type. Such regions can be allotypic and are described by, e.g., Johnson, G., and Wu, T.T., Nucleic Acids Res. 28 (2000) 214-218 and the databases referenced therein and are useful as long as the properties of induction of ADCC and preferably CDC according to the invention are retained.
The term "recombinant human antibody", as used herein, is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies isolated from a host cell such as an SP2-0, NSO or CHO cell (like CHO Kl) or from an animal (e.g. a mouse) that is transgenic for human immunoglobulin genes or antibodies expressed using a recombinant expression vector transfected into a host cell. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences in a rearranged form. The recombinant human antibodies according to the invention have been subjected to in vivo somatic hypermutation. Thus, the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo.
As used herein, "binding" refers to antibody binding to Abeta with an affinity of about 10"13 to 10"8 M (K0), preferably of about 10"13 to 10*9 M. The "constant domains" are not involved directly in binding the antibody to an antigen but are involved in the effector functions (ADCC, complement binding, and CDC). The constant domain of an antibody according to the invention is of the IgGl type. Human constant domains having these characteristics are described in detail by Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991), and by Bruggemann, M., et al., J. Exp. Med. 166 (1987) 1351-1361 ; Love, T.W., et al., Methods Enzymol. 178 (1989) 515-527. Examples are shown in SEQ ID NOs: 5 to 8 in WO 2005/005635. Other useful and preferred constant domains are the constant domains of the antibodies obtainable from the hybridoma cell lines deposited with depositories like DSMZ or ATCC. The constant domains may provide complement binding. ADCC and optionally CDC are provided by the combination of variable and constant domains.
The "variable region" (variable region of a light chain (VL), variable region of a heavy chain (VH)) as used herein denotes each of the pair of light and heavy chains which is involved directly in binding the antibody to the antigen. The domains of variable human light and heavy chains have the same general structure and each domain comprises four framework (FR) regions whose sequences are widely conserved, connected by three "hypervariable regions" (or complementarity determining regions, CDRs). The framework regions adopt a β-sheet conformation and the CDRs may form loops connecting the β-sheet structure. The CDRs in each chain are held in their three-dimensional structure by the framework regions and form together with the CDRs from the other chain the antigen binding site. The antibody heavy and light chain CDR3 regions play a particularly important role in the binding specificity/affinity of the antibodies according to the invention and therefore provide a further object of the invention.
The terms "hypervariable region" or "antigen-binding portion of an antibody" when used herein refer to the amino acid residues of an antibody which are responsible for antigen- binding. The hypervariable region comprises amino acid residues from the "complementarity determining regions" or "CDRs". "Framework" or "FR" regions are those variable domain regions other than the hypervariable region residues as herein defined. Therefore, the light and heavy chains of an antibody comprise from N- to C-terminus the domains FRl, CDRl, FR2, CDR2, FR3, CDR3, and FR4. Especially, CDR3 of the heavy chain is the region which contributes most to antigen binding. CDR and FR regions are determined according to the standard definition of Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and/or those residues from a "hypervariable loop".
The formulation of this invention may, inter alia, comprise "stabilizers", "lyoprotectants", "sugars", "amino acids", "polyols", "antioxidants", "preservatives", "surfactants", "buffers" and/or "tonicity agents".
The term "stabilizer" denotes a pharmaceutical acceptable excipient, which protects the active pharmaceutical ingredient and/ or the formulation from chemical and / or physical degradation during manufacturing, storage and application. Chemical and physical degradation pathways of protein pharmaceuticals are reviewed by Cleland, J. L., M. F. Powell, et al. (1993). "The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation." Crit Rev Ther Drug Carrier Syst 10(4): 307-77, Wang, W. (1999). "Instability, stabilization, and formulation of liquid protein pharmaceuticals." Int J Pharm 185(2): 129-88., Wang, W. (2000). "Lyophilization and development of solid protein pharmaceuticals." Int J Pharm 203(1-2): 1-60. and Chi, E. Y., S. Krishnan, et al. (2003). "Physical stability of proteins in aqueous solution: mechanism and driving forces in normative protein aggregation." Pharm Res 20(9): 1325-36. Stabilizers include but are not limited to sugars, amino acids, polyols, surfactants, antioxidants, preservatives, cyclodextrines, e.g. hydroxypropyl-β-cyclodextrine, sulfobutylethyl-β- cyclodextrin, β-Cyclodextrin, polyethylenglycols, e.g. PEG 3000, 3350, 4000, 6000, albumin, e.g. human serum albumin (HSA), bovines serum albumin (BSA), salts, e.g. sodium chloride, magnesium chloride, calcium chloride, chelators, e.g. EDTA as hereafter defined. As mentioned hereinabove, stabilizers can be present in the formulation in an amount of about 10 to about 500 mM, preferably in an amount of about 10 to about 30OmM and more preferably in an amount of about 10OmM to about 30OmM.
The term "lyoprotectant" denotes pharmaceutical acceptable excipients, which protects the labile active ingredient (e.g. a protein) against destabilizing conditions during the lyophilisation process, subsequent storage and reconstitution. Lyoprotectants comprise but are not limited to the group consisting of sugars, polyols (such as e.g. sugar alcohols) and amino acids. Preferred lyoprotectants can be selected from the group consisting of: sugars such as sucrose, trehalose, lactose, glucose, mannose, maltose, galactose, fructose, sorbose, and rafFinose neuraminic acid and galactosamine, amino sugars such as glucosamine, N- Methylglucosamine ("Meglumine"), polyols such as mannitol, and amino acids such as arginine. Lyoprotectants are generally used in an amount of about 10 to 50OmM, preferably in an amount of about 10 to about 30OmM and more preferably in an amount of about 100 to about 30OmM.
The term "sugar" as used herein denotes a pharmaceutically acceptable carbohydrate used generally in an amount of about 10 mM to about 500 mM, preferably in an amount of about 10 to about 30OmM and more preferably in an amount of about 100 to about 30OmM. Suitable sugars comprise but are not limited to trehalose, sucrose, lactose, glucose, mannose, maltose, galactose, fructose, sorbose, raffinose, glucosamine, N-Methylglucosamine (so- called "Meglumine"), galactosamine and neuraminic acid. Preferred sugars are sucrose and trehalose and more preferably sucrose.
The term "amino acid" as used herein in the context of the pharmaceutical parenteral formulation denotes a pharmaceutical acceptable organic molecule possessing an amino moiety located at α-position to a carboxylic group. Amino acids comprise but not limited to arginine, glycine, ornithine, lysine, histidine, glutamic acid, aspartic acid, isoleucine, leucine, alanine, phenylalanine, tyrosine, tryptophan, methionine, serine, proline and combinations thereof. Amino acids are generally used in an amount of about 10 to 50OmM, preferably in an amount of about 10 to about 30OmM and more preferably in an amount of about 100 to about 30OmM.
The term "polyols" as used herein denotes pharmaceutically acceptable alcohols with more than one hydroxy group. Polyols can be used in an amount of about 10 mM to about 50OmM, preferably in an amount of about 10 to about 300 and more preferably in an amount of about 100 to about 30OmM. Suitable polyols comprise to but are not limited to mannitol, sorbitol, glycerine, dextran, glycerol, arabitol, propylene glycol, polyethylene glycol, and combinations thereof.
The term "antioxidant" denotes pharmaceutically acceptable excipients, which prevent oxidation of the active pharmaceutical ingredient. Antioxidants can be used in an amount of about 1 to about 10OmM, preferably in an amount of about 5 to about 5OmM and more preferably in an amount of about 5 to about 2OmM. Antioxidants comprise but are not limited to ascorbic acid, glutathione, cysteine, methionine, citric acid, EDTA, and combinations thereof.
The term "preservative" denotes pharmaceutically acceptable excipients, which prevent the growth of microorganism in the formulation. For example, the addition of a preservative to a multi-dose formulation protects the formulation against microbial contamination. Preservatives are generally used in an amount of about 0.001 to about 2 %(w/v). Preservatives comprise but are not limited to ethanol, benzyl alcohol, phenol, m-cresol, p- chlor-m-cresol, methyl or propyl parabens, benzalkonium chloride, and combinations thereof.
The term "surfactant" as used herein denotes a pharmaceutically acceptable surfactant. In the formulation of the invention, the amount of surfactant is described a percentage expressed in weight/volume percent (w/v %). Suitable pharmaceutically acceptable surfactants comprise but are not limited to the group of polyoxyethylensorbitan fatty acid esters (T ween), polyoxy ethylene alkyl ethers (Brij), alkylphenylpolyoxyethylene ethers (Triton-X), polyoxyethylene-polyoxypropylene copolymer (Poloxamer, Pluronic)., and sodium dodecyl sulphate (SDS). Preferred polyoxyethylenesorbitan-fatty acid esters are polysorbate 20,(sold under the trademark Tween 20™) and polysorbate 80 (sold under the trademark Tween 80™). Preferred polyethylene-polypropylene copolymers are those sold under the names Pluronic® F68 or Poloxamer 188™. Preferred Polyoxyethylene alkyl ethers are those sold under the trademark Brij™. Preferred alkylphenolpolyoxyethylene ethers are sold under the tradename Triton-X. When polysorbate 20 (Tween 20™) and polysorbate 80(T ween 80™) are used they are generally used in a concentration range of about 0.001 to about 1%, preferably of about 0.005 to about 0.1% and still preferably about 0.01% to about 0.04%w/v.
The term "buffer" as used herein denotes a pharmaceutically acceptable excipient, which stabilizes the pH of a pharmaceutical preparation. Suitable buffers are well known in the art and can be found in the literature. Preferred pharmaceutically acceptable buffers comprise but are not limited to histidine-buffers, citrate-buffers, succinate-buffers and phosphate-buffers. Still preferred buffers comprise L-histidine or mixtures of L-histidine and L-histidine hydrochloride with pH adjustment with an acid or a base known in the art. The abovementioned histidine-buffers are generally used in an amount of about ImM to about 100 mM, preferably of about 5 mM to about 50 mM and still more preferably of about 10-20 mM. Independently from the buffer used, the pH can be adjusted at a value comprising about 4.0 to about 7.0 and preferably about 5.0 to about 6.0 and still preferably about 5.5 with an acid or a base known in the art, e.g., hydrochloric acid, acetic acid, phosphoric acid, sulfuric acid and citric acid, sodium hydroxide and potassium hydroxide
The term "tonicity agents" as used herein denotes pharmaceutically acceptable tonicity agents. Tonicity agents are used to modulate the tonicity of the formulation. The formulation can be hypotonic, isotonic or hypertonic. Isotonicity is generally relates to the osmotic pressure relative of a solution usually relative to that of human blood serum. The formulation according to the invention can be hypotonic, isotonic or hypertonic but will preferably be isotonic. In a concern for clarity it is once more emphasized that an isotonic formulation is liquid or liquid reconstituted from a solid form, e.g. from a lyophilized form and denotes a solution having the same tonicity as some other solution with which it is compared, such as physiologic salt solution and the blood serum. Suitable isotonicity agents comprise but are not limited to sodium chloride, potassium chloride, glycerin and any component from the group of amino acids, sugars, in particular glucose as defined herein as well as combinations thereof. Tonicity agents are used in an amount of about 5 mM to about 500 mM.
The term "liquid" as used herein in connection with the formulation according to the invention denotes a formulation which is liquid at a temperature of at least about 2 to about 8 0C under standard pressure.
The term "lyophilizate" as used herein in connection with the formulation according to the invention denotes a formulation which is manufactured by freeze-drying methods known in the art per se. The solvent (e.g. water) is removed by freezing following sublimation under vacuum and desorption of residual water at elevated temperature. In the pharmaceutical field, the lyophilizate has usually a residual moisture of about 0.1 to 5% (w/w) and is present as a powder or a physical stable cake. The lyophilizate is characterized by a fast dissolution after addition of a reconstirution medium.
The term "reconstituted formulation" as used herein in connection with the formulation according to the invention denotes a formulation which is lyophilized and re-dissolved by addition of reconstirution medium. The reconstirution medium comprises but is not limited to water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solutions (e.g. 0.9% (w/v) NaCl), glucose solutions (e.g. 5% glucose), surfactant containing solutions (e.g. 0.01% polysorbate 20), a pH -buffered solution (e.g. phosphate-buffered solutions) and combinations thereof.
The term "stable formulation" as used herein in connection with the formulation according to the invention denotes a formulation, which preserves its physical and chemical integrity during manufacturing, storage and application. Various analytical techniques for evaluating protein stability are available and reviewed in Reubsaet, J. L., J. H. Beijnen, et al. (1998). "Analytical techniques used to study the degradation of proteins and peptides: chemical instability". J Pharm Biomed Anal 17(6-7): 955-78 and Wang, W. (1999). "Instability, stabilization, and formulation of liquid protein pharmaceuticals." Int J Pharm 185(2): 129-88. Stability can be evaluated by storage at selected climate conditions for a selected time period, by applying mechanical stress such as shaking at a selected shaking frequency for a selected time period, by irradiation with a selected light intensity for a selected period of time, or by repetitive freezing and thawing at selected temperatures.
The term "pharmaceutically acceptable" as used herein in connection with the formulation according to the invention denotes a formulation which is in compliance with the current international regulatory requirements for pharmaceuticals. A pharmaceutical acceptable formulation contains excipients which are generally recognized for the anticipated route of application and concentration range as safe. In addition, it should provide sufficient stability during manufacturing, storage and application. Especially a formulation for a parenteral route of application should fulfill the requirements isotonicity and euhydric pH in comparison to the composition of human blood.
As mentioned above, in one aspect, the invention relates to a stable pharmaceutical parenteral Abeta antibody formulation comprising:
- about 1 to about 250 mg/mL Abeta antibody; about 0.001 to about 1% of at least one surfactant;
- about 1 to about 100 mM of a buffer;
- optionally about 10 to about 500 mM of a stabilizer and/or about 5 to about 500 mM of a tonicity agent
- at a pH of about 4.0 to about 7.0. The Abeta antibody concentration ranges from about 1 to about 250 mg/mL, preferably from about 50 mg/mL to about 200 mg/mL and more preferably from about 150 mg/mL to about 200 mg/mL. For clarity reasons, it is emphasized that the concentrations as indicated herein relate to the concentration in a liquid or in a liquid that is accurately reconstituted from a solid form. Accordingly, the lyophilized formulations as described herein can be reconstituted from a lyophilizate in such way that the resulting reconstituted formula comprises the respective constituents in the concentrations described herein.
However, it is evident for the skilled person that the stable lyophilizates as described herein may also be reconstituted using such an amount of reconstitution medium that the resulting reconstituted formulation is either more concentrated or less concentrated. For instance, the lyophilizate of "Formulation A" as described herein in Table 2 may be reconstituted in such way that the resulting reconstituted formulation is further diluted to comprise e.g. 20mg/mL Abeta antibody, 5.3mM L-histidine, 66.7mM Sucrose and 0.01 1% polysorbate 20; see Formulation R of Table 2.
The formulation according to the invention can be in a liquid form, a lyophilized form or in a liquid form reconstituted from a lyophilized form.
In the cases where the formulation of the invention is in a lyophilized form or in a liquid from reconstituted from a lyophilized form, it can comprise at least one lyoprotectant as stabilizer.
The formulation according to the invention can be administered by intravenous (i.v.), subcutaneous (s.c.) or any other parenteral administration means such as those known in the pharmaceutical art. The formulation according to the invention is preferably administered by subcutaneous ways.
The formulation according to the invention can be prepared by methods known in the art, such as ultrafϊltration-diafiltration, dialysis, addition and mixing, lyophilisation, reconstitution, and combinations thereof. Examples of preparations of formulations according to the invention can be found hereinafter.
In a preferred embodiment, the Abeta antibody comprised in the pharmaceutical parenteral formulation of the present invention may comprise or have the variable region as defined in SEQ ID NO: 1 : QVELVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINASGT
RTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVR
YFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSW
NSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV
EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV
KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKA
LPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNG
QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL
SLSPGK (SEQ ID NO: 1)
This sequence is also depicted herein below and the CDRs, CH-regions, heavy regions as well as two N-glycosylation sites (Asn 52 and Asn 306) are indicated:
QVELVESGGGLVQPGGSLRLSCAASIGFTFSSYAMSlWVRQAPGKGLEWVS
IATNASGTRTYYADSVKGIRFTISRDNSKNTL YLQMNSLRAEDTAVYYCAR
|GKGNTHKPYGYVRYFDV|WGQGTL VTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
VKDYFPEPVTVSWNSGALTSGVHTFPAVLOSSGLYSLSSVVTVPSSSLGTOTYICNV NHKPSNTKVDKKVEP.KS'CD^rHTCPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEOYNSTYRVVSVLTVLHODWL
MMALHNHYTQKSLSLSPGK.(SEQ ID NO: 1)
Figure imgf000016_0001
3 underlined: CHl italics: hinge underlined twice: CH2 dotted underlined;, CH3 bold N: N-linked glycosylation sites
The exemplified Abeta antibody comprising SEQ ID NO: 1 as described herein may also comprise a light chain, said light chain may comprise or have the following amino acid sequence: DΓVLTQSPATLSLSPGERATLSCRASQSVSSSYLA WYQQKPGQ APRLLIYGASSRATG VP ARFSGSGSGTDFTLTISSLEPEDFATYYCLQIYNMPITFGQGTKVEIKRTV AAPSVFI FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 2)
The term "Abeta antibody A", as used herein, relates to the exemplified Abeta antibody comprising a heavy chain as defined in SEQ ID NO: 1 and a light chain as defined in SEQ ID NO: 2.
The term "mono-glycosylated antibody(ies)", as used herein, relates to antibody molecules comprising an N-glycosylation in one (VH)-region of an individual antibody molecule, e.g. of an immunoglobulin, e.g. an IgG, e.g. of an IgGl. For example, said "mono- glycosylated form" comprises a glycosylation on one variable region of the heavy chain e.g. at position asparagine "Asn 52" of the herein described "Abeta antibody A". This "mono- glycosylated IgGl -form or mono-glycosylated isoform" may also comprise, as illustrated herein, the glycosylation in the well conserved glycosylation site in the Fc-part, for example asparagine Asn 306 in the non-variable Fc-part of the herein exemplified "Abeta antibody A".
The term "double-glycosylated antibody(ies)" in the meaning of this invention comprises the herein defined glycosylation on both variable regions of the heavy chain (VH)- region. Again, this "double glycosylated form", comprises a glycosylation on the variable region of both heavy chains, e.g. at position asparagine Asn 52 of the herein exemplified "Abeta antibody A". This "double-glycosylated IgGl -form or double-glycosylated isoform" may also comprise, as illustrated herein, the glycosylation in the well conserved glycosylation site in the non-variable/constant Fc-part, in particular on position 306 of the exemplified "Abeta antibody A". Appended figure 1 illustrates corresponding antibody molecules.
Antibodies devoid of such a post-translational modification in the variable region, e.g. in both variable regions of the heavy chain (both (VH)-regions) are, in context of this invention considered as a "non-glycosylated form", comprising no glycosylation in the variable region of the heavy chain. Yet, this "non-glycosylated form" may nevertheless comprise (a) glycosylation(s) in the constant region (C-region) of the antibody, for example, and most commonly at the well conserved glycosylation site of the Fc-part, in particular the asparagine (Asn) 306 in the non- variable/constant Fc-part as defined herein; see also SEQ ID NO: 1.
The pharmaceutical parenteral formulations of the invention may comprise the exemplary "Abeta antibody A" as defined herein above and as illustrated in the appended examples. Accordingly, said pharmaceutical parenteral formulations comprising Abeta antibody A may comprise mono-glycosylated Abeta antibody A or double-glycosylated Abeta antibody A or non-glycosylated Abeta antibody A or mixtures thereof as defined above.
Purification of glycosylation isoforms of recombinantly expressed Abeta antibody molecules may comprise the steps of:
(1) protein A column purification;
(2) ion exchange column purification, e.g. a cation exchange chromatography; and, optionally,
(3) size exclusion column purification.
The purification protocol may comprise further steps, like further concentration steps, e.g. diafiltration or analytical steps, e.g. involving analytical columns. It is also envisaged and feasible that particular certain steps are repeated (e.g. two ion exchange chromatography steps may be carried out) or that certain steps (e.g. size exclusion chromatography) may be omitted.
Protein A is a group specific ligand which binds to the Fc region of most IgGl isotypes. It is synthesized by some strains of Staphylococcus aureus and can be isolated therefrom and coupled to chromatographic beads. Several types of gel preparations are available commercially. An example for a protein A column which may be used is a MabSelect (Trademark) column. Ideally the column is equilibrated with 25 mM Tris/HCl, 25 mM NaCl, 5 mM EDTA, the cell culture supernatant is loaded onto the column, the column is washed with 1 M Tris/HCl pH 7,2 and the antibody is eluted at pH 3.2 using 100 mM acetic acid.
Cation-exchange chromatography exploits interactions between positively charged groups in a stationary phase and the sample which is in the mobile phase. When a weak cation exchanger (e.g. CM Toyopearl 650®) is used, the following chromatographic steps are performed: After preequilibration with 100 mM acetic acid pH 4, loading of Protein A eluate and washing with 100 mM acetic acid pH 4 the antibody is eluted and fractionated by applying steps of 250 mM sodium acetate (pH 7.8-8.5) and 500 mM sodium acetate (pH 7.8- 8.5). With the first step a mixture of double-glycosylated isoform fraction and mono- glycosylated isoform fraction are normally eluted, using the second step the non-glycosylated isoform fraction is normally eluted.
From a strong cation exchanger (e.g. SP Toyopearl 650) the antibody can be eluted by salt steps: After equilibration of the column with 50 mM acetic acid pH 5.0, loading the Protein A eluate with pH 4 the first elution step using 50 mM acetic acid and 210 mM sodium chloride is performed. Then a second elution step of 50 mM acetic acid and 350 mM sodium chloride is applied. By the first salt step a mixture of the double-glycosylated isoform fraction and mono-glycosylated isoform fraction are normally eluted, by the second salt step the non-glycosylated isoform is normally eluted.
In addition the antibody may also be eluted from a strong cation exchanger column (e.g. SP-Sepharose®) by a salt gradient: After preequilibration, loading and washing the column at pH 4.5 a salt gradient is applied from 50 mM MES pH 5.8 to 50 mM MES /1 M sodium chloride pH 5.8. Here the double-glycosylated isoform, mono-glycosylated isoform and non-glycosylated isoform fractions are normally eluted separately. In the following double-glycosylated isoform fraction and mono-glycosylated isoform fraction may be pooled to result in the product pool and/or a desired antibody mixture.
Further purification of the mixture of double- and mono-glycosylated antibody molecules, e.g. immunoglobulins, may be performed by size exclusion chromatography. An example of a useful column is a Superdex 200® column. Examples of running buffers include histidine/sodium chloride, e.g. 10 mM histidine/125 mM sodium chloride/pH 6, and phosphate buffered saline (PBS).
Anion exchange chromatography in the flow through mode followed by a concentration/ diafiltration is an alternative purification step. Q Sepharose® is an example for a resin for the anion exchange step. For example, the eluate from the SP chromatography may be threefold diluted with 37,5 mM Tris/HCl pH 7.9 and passed over a Q-Sepharose column pre-equilibrated with 25 mM Tris/83 mM sodium acetate. The flow through is collected, adjusted to pH 5.5 and concentrated by ultrafiltration using e.g. a Hydrosart 30 kD® membrane. In the following the concentrate may be diafiltrated against for example 10 volumes of 20 mM histidine/HCl pH 5.5.
As defined above, antibody isoforms may also comprise (a) further glycosylation(s) in the constant/non- variable part of the antibody molecules, e.g. in the Fc-part of an IgG, e.g. in the Fc-part in an IgGl. Said glycosylation in the Fc-part relates to a well conserved glycosylation, being characterized in located on position Asn306 of the heavy chain, e.g., in accordance with the herein defined SEQ ID NO: 1.
The IgG-Fc region of the antibodies comprised in the formulations of this invention may be a homodimer comprised of inter-chain disulphide bonded hinge regions, glycosylated CH2 domains, bearing N-linked oligosaccharide at asparagine 306 (Asn-306) of the CH2 and non-covalently paired CH3 domains. The oligosaccharide of the glycosylation at Asn-306 is of the complex biantennary type and may comprise a core heptasaccharide structure with variable addition of outer arm sugars.
The oligosaccharide influences or determines Fc structure and function (Jefferis (1998) Immunol Rev. 163, 50-76). Effector functions, numbering particular specific IgG-Fc/effector ligand interactions have been discussed (Jefferis (2002) Immunol Lett. 82(1-2), 57-65 and Krapp (2003) J MoI Biol. 325(5), 979-89). This conserved Fc-position Asn-306 corresponds to "Asn-297" in the Kabat-system (Kabat (1991) Sequences of Proteins of Immunological Interest, 5th Ed., Public Health Service, National Institutes of Health, Bethesda MD.)
In a certain embodiment, the formulation of the invention is a liquid or lyophilized formulation comprising:
- about 1 to about 200 mg/mL Abeta antibody ,
- 0.04% Tween 20 w/v,
- 20 mM L-histidine,
- 250 mM Sucrose,
- at pH 5.5.
In another embodiment, the formulation according to the invention also comprises a lyophilized formulation comprising:
- 75 mg/mL Abeta antibody ,
- 0.04% Tween 20 w/v, - 20 mM L-histidine, -250 mM Sucrose, -atpH5.5.
or
- 75 mg/mL Abeta antibody ,
- 0.02% Tween 20 w/v,
- 20 mM L-histidine,
- 250 mM Sucrose, -atpH5.5.
In yet another embodiment, the formulation according to the invention also comprises a liquid formulation comprising:
- 37.5 mg/mL Abeta antibody ,
- 0.02% Tween 20 w/v, - 10 mM L-histidine,
- 125 mM Sucrose,
-atpH5.5. or
- 37.5 mg/mL Abeta antibody , -0.01% Tween 20 w/v,
- 10 mM L-histidine, - 125 mM Sucrose, -atpH5.5.
In still another embodiment, the formulation according to the invention also comprises a lyophilized formulation comprising:
- 15 mg/mL Abeta antibody ,
- 0.04% Tween 20 w/v,
- 20 mM L-histidine,
- 250 mM Sucrose, -atpH5.5. In still another embodiment, the formulation according to the invention also comprises a lyophilized formulation comprising:
- 20 mg/mL Abeta antibody , - 0.011% Tween 20 w/v,
- 5.3 mM L-histidine,
- 66.7 mM Sucrose, at pH 5.5.
In still another embodiment, the formulation according to the invention also comprises a liquid formulation comprising:
- 7.5 mg/mL Abeta antibody ,
- 0.04% Tween 20 w/v,
- 20 mM L-histidine, - 25O mM Sucrose, - at pH 5.5; or
- 7.5 mg/mL Abeta antibody ,
- 0.02% Tween 20 w/v, - 10 mM L-histidine,
- 125 mM Sucrose, at pH 5.5.
In a further embodiment, the formulation according to the invention also comprises a lyophilized formulation comprising:
- 75 mg/mL Abeta antibody ,
- 0.04% Tween 20 w/v,
- 20 mM L-histidine,
- 250 mM Trehalose, - at pH 5.5. or
- 75 mg/mL Abeta antibody , - 0.02% Jween 20 w/v,
- 20 mM L-histidine,
- 250 mM Trehalose, - at pH 5.5.
In still another embodiment, the formulation according to the invention also comprises a liquid formulation comprising:
- 37.5 mg/mL Abeta antibody ,
- 0.02% Tween 20 w/v, - 10 mM L-histidine,
- 125 mM Trehalose,
- at pH 5.5. or
- 37.5 mg/mL Abeta antibody , - 0.01% Tween 20 w/v,
- 10 mM L-histidine, - 125 mM Trehalose, - at pH 5.5.
In still another embodiment, the formulation according to the invention also comprises a liquid formulation comprising:
- 75 mg/mL Abeta antibody ,
- 0.02% Tween 20 w/v,
- 20 mM L-histidine,
- 250 mM Trehalose, - at pH 5.5. or
- 75 mg/mL Abeta antibody ,
- 0.02% Tween 20 w/v,
- 20 mM L-histidine,
- 250 mM Mannitol, -atpH5.5. or
- 75 mg/mL Abeta antibody ,
- 0.02% Tween 20 w/v,
- 20 mM L-histidine,
- 140 mM Sodium Chloride,
-atpH5.5. or
- 150 mg/mL Abeta antibody ,
- 0.02% Tween 20 w/v,
- 20 mM L-histidine,
- 250 mM Trehalose, -atpH5.5. or
- 150 mg/mL Abeta antibody ,
- 0.02% Tween 20 w/v,
- 20 mM L-histidine,
- 250 mM Mannitol, -atpH5.5. or
- 150 mg/mL Abeta antibody , -0.02% Tween 20 w/v,
- 20 mM L-histidine,
- 140 mM Sodium Chloride,
-atpH5.5. or
- 10 mg/mL Abeta antibody ,
- 0.01% Tween 20 w/v, - 20 mM L-histidine,
- 140 mM Sodium chloride,
- at pH 5.5
In a preferred embodiment, the formulation according to the invention also comprises a liquid formulation comprising:
- 10 mg/mL Abeta antibody ,
- 0.01% Tween 20 w/v,
- 20 mM L-histidine,
- 140 mM Sodium chloride, at pH 5.5
In another preferred embodiment, the formulation according to the invention also comprises a lyophilized formulation comprising:
- 75 mg/mL Abeta antibody ,
- 0.04% Tween 20 w/v,
- 20 mM L-histidine,
- 250 mM Sucrose, at pH 5.5
In another preferred embodiment, the formulation according to the invention also comprises a lyophilized formulation comprising:
- 20 mg/mL Abeta antibody , - 0.011% Tween 20 w/v,
- 5.3 mM L-histidine,
- 66.7 mM Sucrose at pH 5.5 FIGURE LEGENDS
Figure 1 Scheme of double-, mono- and non-glycosylated antibody molecules (immunoglobulins).
Figure 2 Content of monomer as determined by size-exclusion chromatography of Abeta antibody A formulations after start and incubation at 5°C, 25°C/60%rh and 40°C/75%rh for up to 6 months. Antibody preparations are freeze-dried and reconstituted to nominal concentration of 75mg/mL.
Figure 3 Content of monomer as determined by size-exclusion chromatography of Abeta antibody A formulations after start and incubation at 5°C, 25°C/60%rh and 40°C/75%rh for 3 months. Antibody preparations K, L and N are formulated at 75mg/mL, whereas preparations O, P and Q are formulated at 150mg/mL.
EXAMPLES
Liquid and lyophilized drug product formulations for subcutaneous administration according to the invention were developed as follows:
Preparation of liquid formulations
Abeta antibody comprising a heavy chain as defined in SEQ ID NO: 1 and a light chain as defined in SEQ ID NO: 2 ("Abeta antibody A" in the context of the present invention) was prepared and obtained as described in WO 03/070760 and was concentrated by ultrafiltration to a concentration of approx. 40 to about 200 mg/mL in a 20 mM histidine buffer at a pH of approx. 5.5. The concentrated solution was then diluted with the formulation buffer (containing sugar (respectively salt or polyol), surfactant and buffer at a pH of approx. pH 5.5) resulting the anticipated antibody concentration of approx. 7.5mg/mL, 37.5 mg/mL, 75 mg/mL or 150mg/mL formulated in the final bulk composition (e.g. 10 mM L-histidine, 125 mM sucrose, 0.02% Tween 20, at pH 5.5).
Alternatively, Abeta antibody A was buffer-exchanged against a diafiltration buffer containing the anticipated buffer and sugar composition and concentrated to an antibody concentration equal or higher than the final concentration of approx. 37.5mg/mL. The surfactant was added after completion of the ultrafiltration operation as a 100 to 200-fold stock solution to the antibody solution. The concentrated antibody solution was adjusted with a formulation buffer containing the identical excipient composition to the final Abeta antibody A concentration of approx. 37.5 mg/mL.
All formulations were sterile-filtered through 0.22 μm low protein binding filters and aseptically filled under nitrogen atmosphere into sterile 6 mL glass vials closed with ETFE (Copolymer of ethylene and tetrafluoroethylene) -coated rubber stoppers and alucrimp caps. The fill volume was approx. 2.4 mL. These formulations were stored at different climate conditions for different intervals of time and stressed by shaking (1 week at a shaking frequency of 200 min"1 at 5°C) and freeze-thaw stress methods. The samples were analyzed before and after applying the stress tests by the analytical methods 1) UV spectrophotometry, 2) Size Exclusion Chromatography (SEC) and 3) nephelometry to determine the turbidity of the solution.
Preparation of lvophilized formulations and liquid formulations reconstituted from such lyophilized formulations
Solutions of approx. 37.5 mg/ml "Abeta antibody A" were prepared as described above for liquid formulations. Any lyophilization method known in the art is intended to be within the scope of the invention. For example, the lyophilization process used for this study included the cooling of the formulation from room temperature to approx 5°C (pre-cooling) and a freezing step to -40°C at a plate cooling rate of approx. l°C/min, followed by a holding step at -4O0C for about 2 hours . The first drying step was performed at a plate temperature of approx. -25°C and a chamber pressure of approx. 80 μbar for about 62 hours. Subsequently, the second drying step started with a temperature ramp of 0.2°C / min from -25°C to 250C, followed by a holding step at 25°C for at least 5 hours at a chamber pressure of approx. 80 μbar (the applied drying schedule is presented in Table 1.)
Lyophilization was carried out in an Usifroid SMH-90 LN2 freeze-dryer (Usifroid, Maurepas, France). All lyophilized cakes in this study had a residual water content of about 0.1 to 1.0% as determined by Karl-Fischer method. The freeze-dried samples were incubated at different temperatures for different intervals of time.
The lyophilized formulations were reconstituted to a final volume of 1.2 mL with water for injection (WFI) yielding an isotonic formulation with an antibody concentration of approx. 75 mg/mL and a viscosity of less than 3 mPa-s. The reconstitution time of the freeze- dried cakes was about 2 to 4min. Analysis of the reconstituted samples was either performed immediately after reconstitution, or after a 24 hour incubation period of the reconstituted liquid sample at 250C.
The samples were analyzed by 1) UV spectrophotometry, 2) determination of the reconstitution time, 3) Size Exclusion Chromatography (SEC) and 4) method of nephelometry to determine the turbidity of the solution.
Size Exclusion Chromatography (SEC) was used to detect soluble high molecular weight species (aggregates) and low molecular weight hydrolysis products (LMW) in the formulations. The method was performed on a Merck Hitachi 7000 HPLC instrument equipped with a Tosohaas TSK G3000 SWXL column. Intact monomer, aggregates and hydrolysis products are separated by an isocratic elution profile, using 0.2M K2HPO4 / 0.25M KCL, pH 7.0 as mobile phase, and were detected at a wavelength of 280nm.
UV spectroscopy, used for determination of protein content, was performed on a Varian Cary Bio UV spectrophotometer at 280 nm. Neat protein samples were diluted to approx. 0.5 mg/mL with 20 mM L-histidine, pH 5.5. The protein concentration was calculated according equation 1.
. ,
Equation 1 :
Figure imgf000028_0001
The protein concentration was measured with a precision of ±10%. The UV light absorption at 280 nm was corrected for light scattering at 320 nm and multiplied with the dilution factor, which was determined from the weighed masses and densities of the neat sample and the dilution buffer. The numerator was divided by the product of the cuvette's path length d and the extinction coefficient ε.
Clarity and the degree of opalescence were measured as Formazin Turbidity Units (FTU) by the method of nephelometry. The neat sample was transferred into a l l mm diameter clear-glass tube and placed into a HACH 2100 AN turbidimeter. Table 1 Freeze-drying Cycle type I
Figure imgf000029_0001
Table 2 Compositions of "Abeta antibody A" drug product formulations according to the invention
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
(*) taking into account the analytical precision and slight variability of reconstitution.
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000037_0002
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
(*) taking into account the analytical precision and slight variability of reconstitution.

Claims

Claims
1. A stable pharmaceutical parenteral Abeta antibody formulation comprising: about 1 to about 250 mg/mL Abeta antibody;
- about 0.001 to about 1% of at least one surfactant;
- about 1 to about 100 mM of a buffer;
- optionally about 10 to about 500 mM of a stabilizer and/or about 5 to about 500 mM of a tonicity agent;
- at a pH of about 4.0 to about 7.0.
2. The formulation according to claim 1 wherein it is a liquid formulation.
3. The formulation according to claim 1 wherein it is a lyophilized formulation.
4. The formulation according to claim 1 wherein it is a liquid formulation reconstituted from a lyophilized formulation.
5. The formulation according to any one of claims 1 to 4, wherein the Abeta antibody concentration is of about 1 to about 200 mg/mL.
6. The formulation according to claim 5 wherein the Abeta antibody concentration is of about 50 mg/mL to about 200 mg/mL.
7. The formulation according to claim 6 wherein the Abeta antibody concentration is of about 150 mg/mL to about 200 mg/mL.
8. The formulation according to any one of claims 1 to 7 wherein the stabilizer is present in the formulation in an amount of about 10 to about 30OmM.
9. The formulation according to claim 1 to 7, wherein the stabilizer is present in the formulation in an amount of about 100 to about 30OmM
10. The formulation according to any one of claims 1 to 9, wherein the stabilizer is selected from the group consisting of sugars, amino acids, polyols, surfactants, antioxidants, preservatives, cyclodextrines, in particular hydroxypropyl-β-cyclodextrine, sulfobutylethyl- β-cyclodextrin and β-cyclodextrin, polyethylenglycols, in particular PEG 3000, 3350, 4000 and 6000, albumin, human serum albumin (HSA), bovines serum albumin (BSA), salts in particular sodium chloride, magnesium chloride, calcium chloride and chelators, in particular EDTA.
11. The formulation according to any one of claims 1 to 10, wherein the stabilizer is a lyoprotectant.
12. The formulation according to claim 11, wherein the lyoprotectant is selected from the group consisting of sugars, amino acids, polyols and sugar alcohols.
13 The formulation according to claim 12, wherein the lyoprotectant is selected from the group consisting of trehalose, sucrose, mannitol, lactose, glucose, mannose, maltose, galactose, fructose, sorbose, raffinose, glucosamine, N-Methylglucosamine ("Meglumine"), galactosamine, neuraminic acid and arginine.
14. The formulation according to any one of claims 1 to 13 wherein the surfactant is present in the formulation in an amount of about 0.005 to about 0.1 % w/v.
15. The formulation according to claim 14, wherein the surfactant is present in the formulation in an amount of about 0.01% to about 0.04%w/v
16. The formulation according to any one of claims 1 to 15 wherein the surfactant is selected from the group consisting of polyoxyethylensorbitan fatty acid esters, polyoxyethylene alkyl ethers, alkylphenylpolyoxyethylene ethers, polyoxy ethyl ene- polyoxypropylene copolymer and sodium dodecyl sulphate
17. The formulation according to claim 16, wherein the surfactant is selected from the group of polyoxyethylene sorbitan monolaureate and polyoxyethylene sorbitan monooleate, poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338 and poloxamer 407, polyoxyethylene (23) lauryl ether, polyoxyethylene (20) cetyl ether, polyoxyethylene (10) oleyl ether and polyoxyethylene (20) oleyl ether, and octyl phenol ethoxylate (7.5), octyl phenol ethoxylate (9.5), and octyl phenol ethoxylate (102).
18. The formulation according to claim 17, wherein the surfactant is selected from the group containing polyoxyethylene sorbitan monolaureate and polyoxyethylene sorbitan monooleate
19. The formulation according to any one of claims 1 to 18 wherein the buffer is present in the formulation in an amount of about ImM to about 100 mM.
20. The formulation according to claim 15, wherein the buffer is present in the formulation in an amount of about 5 mM to about 50 mM.
21. The formulation according to claim 20, wherein the buffer is present in the formulation in an amount of about 10 to about 20 mM.
22. The formulation according to any one of claims 1 to 21 wherein the buffer is selected from the group consisting of histidine-buffers, citrate-buffers, succinate-buffers, acetate-buffers and phosphate-buffers.
23. The formulation according to claim 22 wherein the buffer comprises L-histidine or mixtures of L-histidine with L-histidine hydrochloride.
24. The formulation according to any one of claims 1 to 23, wherein the pH is about 4.0 to about 7.0.
25. The formulation according to claim 24, wherein the pH is about 5.0 to about 6.0.
26. The formulation according to claim 25, wherein the pH is about 5.5.
27. The formulation according to any one of claims 1 to 26, which comprises one or more tonicity agents.
28. The formulation according to any one of claims 1 to 27, wherein the tonicity agent is present in the formulation in an amount of about 5 mM to about 500 mM.
29. The formulation according to any one of claims 1 to 28, wherein the tonicity agents are selected from the group consisting of sodium chloride, potassium chloride, glycerin, amino acids, sugars, as well as combinations thereof.
30. The formulation according to any one of claim 1 to 29, which can be administered by intravenous (i.v.) or subcutaneous (s.c.) or any other parenteral administration.
31. The liquid formulation of claim 2 which comprises:
- about 1 to about 200 mg/mL Abeta antibody,
- 0.04% Tween 20 w/v, - 20 mM L-histidine,
- 250 mM Sucrose,
- atpH5.5;
or
- 37.5 mg/mL Abeta antibody ,
- 0.02% Tween 20 w/v, - 10 mM L-histidine,
- 125 mM Sucrose,
-atpH5.5; or
- 37.5 mg/mL Abeta antibody , -0.01% Tween 20 w/v, -1OmM L-histidine,
- 125 mM Sucrose,
-atpH5.5; or
- 7.5 mg/mL Abeta antibody ,
- 0.04% Tween 20 w/v,
- 20 mM L-histidine, -25OmM Sucrose, -atpH5.5; or
- 7.5 mg/mL Abeta antibody ,
- 0.02% Tween 20 w/v, - 10 mM L-histidine,
- 125 mM Sucrose, -atpH5.5; or
- 37.5 mg/mL Abeta antibody , - 0.02% Tween 20 w/v, - 10 mM L-histidine,
- 125 mM Trehalose,
-atpH5.5; or
- 37.5 mg/mL Abeta antibody , -0.01% Tween 20 w/v,
- 10 mM L-histidine, - 125 mM Trehalose, -atpH5.5. or
- 75 mg/mL Abeta antibody , -0.02% Tween 20 w/v,
- 20 mM L-histidine,
- 250 mM Trehalose, -atpH5.5. or
- 75 mg/mL Abeta antibody ,
- 0.02% Tween 20 w/v,
- 20 mM L-histidine, -250mMMannitol, -atpH5.5. or
- 75 mg/mL Abeta antibody ,
- 0.02% Tween 20 w/v,
- 20 mM L-histidine,
- 140 mM Sodium chloride, -atpH5.5. or
- 150 mg/mL Abeta antibody ,
- 0.02% Tween 20 w/v,
- 20 mM L-histidine,
- 250 mM Trehalose, -atpH5.5. or
- 150 mg/mL Abeta antibody ,
- 0.02% Tween 20 w/v,
- 20 mM L-histidine,
- 250 mM Mannitol, -atpH5.5. or
- 150 mg/mL Abeta antibody ,
- 0.02% Tween 20 w/v,
- 20 mM L-histidine,
- 140 mM Sodium chloride, -atpH5.5; or
- 10 mg/mL Abeta antibody ,
- 0.01% Tween 20 w/v,
- 20 mM L-histidine,
- 140 mM Sodium chloride, -atpH5.5.
32. The lyophilized formulation of claim 3 which comprises: - about 1 to about 200 mg/mL Abeta antibody ,
- 0.04% Tween 20 w/v,
- 20 mM L-histidine,
- 250 mM Sucrose,
- atpH5.5;
or
- 75 mg/mL Abeta antibody ,
- 0.04% Tween 20 w/v,
- 20 mM L-histidine, -25OmM Sucrose, -atpH5.5; or
- 75 mg/mL Abeta antibody ,
- 0.02% Tween 20 w/v,
- 20 mM L-histidine,
- 250 mM Sucrose, -atpH5.5; or
- 15 mg/mL Abeta antibody ,
- 0.04% Tween 20 w/v,
- 20 mM L-histidine,
- 250 mM Sucrose, -atpH5.5; or
- 75 mg/mL Abeta antibody ,
- 0.04% Tween 20 w/v,
- 20 mM L-histidine,
- 250 mM Trehalose, -atpH5.5. or
- 75 mg/mL Abeta antibody ,
- 0.02% Tween 20 w/v,
- 20 mM L-histidine,
- 250 mM Trehalose, at pH 5.5
or
- 20 mg/mL Abeta antibody ,
- 0.011 % Tween 20 w/v,
- 5.3 mM L-histidine,
- 66.7 mM Sucrose, at pH 5.5.
33. The liquid formulation of claim 2 or 31 which comprises:
- 10 mg/mL Abeta antibody ,
- 0.01% Tween 20 w/v,
- 20 mM L-histidine,
- 140 mM Sodium chloride, at pH 5.5.
34. The lyophilized formulation of claim 3 or 32 which comprises:
- 75 mg/mL Abeta antibody ,
- 0.04% Tween 20 w/v,
- 20 mM L-histidine,
- 250 mM Sucrose, at pH 5.5.
35. The lyophilized formulation of claim 3 or 32 which comprises:
- 20 mg/mL Abeta antibody , - 0.011% Tween 20 w/v, - 5.3 mM L-histidine,
- 66.7 mM Sucrose, at pH 5.5.
36. The formulation according to claims 1 to 35, wherein the Abeta antibody comprises at least one antigen binding site comprising a glycosylated asparagine (Asn) in the variable region of the heavy chain (VH).
37. The formulation according to claim 1 to 36, wherein the Abeta antibody is a defined mixture of
(a) Abeta antibody, wherein one of the antigen binding sites comprises a glycosylated asparagine (Asn) in the variable region of the heavy chain (VH); and
(b) Abeta antibody, wherein both antigen binding sites comprise a glycosylated asparagine (Asn) in the variable region of the heavy chain (VH); and which is free of or comprises to a very low extent Abeta antibody, wherein none of the antigen binding site comprises a glycosylated asparagine (Asn) in the variable region of the heavy chain (VH).
38. The formulation according to claim 36 or 37, wherein the glycosylated asparagine (Asn) in the variable region of the heavy chain (VH) is a glycosylated asparagine (Asn) in the CDR-2 region of the heavy chain (VH).
39. The formulation according to claims 1 to 38, wherein the Abeta antibody comprises a heavy chain as defined in SEQ ID NO: 1 and a light chain as defined in SEQ ID NO: 2.
40. Use of a formulation according to any one of claims 1 to 39 for the preparation of a medicament useful for treating Alzheimer's disease.
41. The invention as described hereinabove.
PCT/EP2007/010825 2006-11-12 2007-12-11 Abeta antibody parenteral formulation WO2008071394A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
MX2009006199A MX2009006199A (en) 2006-12-11 2007-12-11 Abeta antibody parenteral formulation.
BRPI0721097-3A BRPI0721097A2 (en) 2006-12-11 2007-12-11 PARENTERAL FORMULATION OF OPEN ANTIBODY
AU2007331712A AU2007331712A1 (en) 2006-12-11 2007-12-11 Abeta antibody parenteral formulation
KR1020097013954A KR20090104017A (en) 2006-12-11 2007-12-11 Abeta antibody parenteral formulation
JP2009540650A JP2010512356A (en) 2006-12-11 2007-12-11 Parenteral Abeta antibody preparation
EP07856573A EP2094729A1 (en) 2006-12-11 2007-12-11 Abeta antibody parenteral formulation
CA002671968A CA2671968A1 (en) 2006-12-11 2007-12-11 Abeta antibody parenteral formulation
US12/448,190 US20110070225A1 (en) 2006-11-12 2007-12-11 Beta antibody parenteral formulation
IL198963A IL198963A0 (en) 2006-12-11 2009-05-26 Abeta antibody parenteral formulation
NO20092586A NO20092586L (en) 2006-12-11 2009-07-07 A-beta antibody parenteral formulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06025590.8 2006-12-11
EP06025590 2006-12-11

Publications (1)

Publication Number Publication Date
WO2008071394A1 true WO2008071394A1 (en) 2008-06-19

Family

ID=39190366

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/010825 WO2008071394A1 (en) 2006-11-12 2007-12-11 Abeta antibody parenteral formulation

Country Status (21)

Country Link
US (1) US20110070225A1 (en)
EP (1) EP2094729A1 (en)
JP (1) JP2010512356A (en)
KR (1) KR20090104017A (en)
CN (1) CN101553504A (en)
AR (1) AR064220A1 (en)
AU (1) AU2007331712A1 (en)
BR (1) BRPI0721097A2 (en)
CA (1) CA2671968A1 (en)
CL (1) CL2007003583A1 (en)
CR (1) CR10823A (en)
EC (1) ECSP099403A (en)
IL (1) IL198963A0 (en)
MA (1) MA30975B1 (en)
MX (1) MX2009006199A (en)
NO (1) NO20092586L (en)
PE (1) PE20081477A1 (en)
RU (1) RU2009126420A (en)
TW (1) TW200831133A (en)
WO (1) WO2008071394A1 (en)
ZA (1) ZA200904014B (en)

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074903A1 (en) * 2008-09-19 2010-03-25 Ulla Grauschopf Novel antibody formulation
WO2010069858A1 (en) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
WO2010100179A2 (en) * 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2011061712A1 (en) * 2009-11-20 2011-05-26 Biocon Limited Formulations of antibody
WO2011090088A1 (en) 2010-01-20 2011-07-28 中外製薬株式会社 Solution preparation containing stabilized antibody
EP2358395A1 (en) * 2008-11-17 2011-08-24 F. Hoffmann-La Roche AG Method and formulation for reducing aggregation of a macromolecule under physiological conditions
US8008073B2 (en) 2003-12-12 2011-08-30 Chugai Seiyaku Kabushiki Kaisha Anti-Mpl antibodies
WO2011104381A2 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
WO2011147921A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
WO2012028683A1 (en) * 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
JP2012511540A (en) * 2008-12-10 2012-05-24 ノバルティス アーゲー Antibody preparation
WO2012151247A3 (en) * 2011-05-02 2013-02-28 Millennium Pharmaceuticals, Inc. FORMULATION FOR ANTI-α4β7 ANTIBODY
JP2013515754A (en) * 2009-12-29 2013-05-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Novel antibody formulation
RU2481824C2 (en) * 2008-10-29 2013-05-20 Аблинкс Н.В Preparations of single domain antigen-binding molecules
WO2013131866A1 (en) * 2012-03-08 2013-09-12 F. Hoffmann-La Roche Ag Abeta antibody formulation
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
WO2014036071A1 (en) * 2012-08-31 2014-03-06 Bayer Healthcare Llc Antibody and protein formulations
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9089529B2 (en) 2011-10-25 2015-07-28 Prothena Therapeutics Limited Antibody formulations and methods
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9175094B2 (en) 2007-06-12 2015-11-03 Ac Immune S.A. Monoclonal antibody
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US9211330B2 (en) 2010-03-03 2015-12-15 Ablynx N.V. A-beta binding polypeptides
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9241994B2 (en) 2005-06-10 2016-01-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
WO2016205037A1 (en) * 2015-06-17 2016-12-22 Eli Lilly And Company Anti-cgrp antibody formulation
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2017051273A1 (en) * 2015-09-22 2017-03-30 Pfizer Inc. Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
JP2017071627A (en) * 2008-06-20 2017-04-13 ノバルティス アーゲー Immunoglobulin with reduced aggregation
US9663579B2 (en) 2011-05-02 2017-05-30 Millennium Pharmaceuticals, Inc. Formulation for anti-α4β7 antibody
US10000573B2 (en) 2008-03-14 2018-06-19 Centro De Immunologia Molecular Monoclonal antibody and a method thereof
CN108373494A (en) * 2018-02-27 2018-08-07 武汉伊艾博科技有限公司 A kind of protection technique preventing Proteolysis of recombinant proteins
US10118962B2 (en) 2008-10-29 2018-11-06 Ablynx N.V. Methods for purification of single domain antigen binding molecules
USRE47150E1 (en) 2010-03-01 2018-12-04 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
EP2841561B1 (en) 2012-04-24 2019-01-16 F.Hoffmann-La Roche Ag Cell culture compositions and methods for polypeptide production
US10189899B2 (en) 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
US10208109B2 (en) 2005-11-30 2019-02-19 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
US10413593B2 (en) 2014-10-24 2019-09-17 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and GLP-1 receptors
US10525137B2 (en) 2015-12-30 2020-01-07 Genentech, Inc. Formulations with reduced degradation of polysorbate
US11242401B2 (en) 2016-10-21 2022-02-08 Biocon Limited Monoclonal antibody and a method of use for the treatment of lupus
WO2022072255A1 (en) * 2020-09-30 2022-04-07 Merck Sharp & Dohme Corp. Binding proteins and antigen binding fragments thereof that bind abeta
RU2779389C2 (en) * 2015-09-22 2022-09-06 Пфайзер Инк. Method for production of therapeutic protein preparation, and preparation based on antibodies, obtained by such a method
US11584793B2 (en) 2015-06-24 2023-02-21 Hoffmann-La Roche Inc. Anti-transferrin receptor antibodies with tailored affinity
US11603411B2 (en) 2015-10-02 2023-03-14 Hoffmann-La Roche Inc. Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
PE20100684A1 (en) * 2005-12-12 2010-10-04 Hoffmann La Roche ANTI B-4-AMYLOID ANTIBODY CONTAINING GLYCOSYLATED ASPARAGINE IN THE VARIABLE REGION OF VH
WO2012151199A1 (en) 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
JP6265970B2 (en) * 2012-03-26 2018-01-24 サノフイ Formulation of a stable IgG4-based binder
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
CA2906101A1 (en) * 2013-03-15 2014-09-18 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
WO2016080367A1 (en) * 2014-11-18 2016-05-26 塩野義製薬株式会社 Stable peptide composition
CN104946616A (en) * 2015-05-12 2015-09-30 骏实生物科技(上海)有限公司 General solid stabilizer used for in vitro diagnostic reagent and application method of general solid stabilizer
ES2818229T3 (en) * 2015-08-19 2021-04-09 Astrazeneca Ab Stable anti-IFNAR1 formulation
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
CN106620691B (en) * 2015-11-04 2020-08-21 信达生物制药(苏州)有限公司 Recombinant fully human anti-CTLA-4 monoclonal antibody preparation and application thereof
CN106199007B (en) * 2016-08-03 2017-04-05 烟台普罗吉生物科技发展有限公司 Protein protective agent
CN106913869B (en) * 2017-03-17 2020-07-28 信达生物制药(苏州)有限公司 anti-CT L A-4 monoclonal antibody preparation and application thereof
EP3606964A4 (en) 2017-04-03 2020-12-09 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
EA202090555A1 (en) * 2017-08-22 2020-06-08 Байоджен Ма Инк. PHARMACEUTICAL COMPOSITIONS CONTAINING BETA AMYLOID ANTIBODIES
MX2021009851A (en) 2019-02-18 2021-09-10 Lilly Co Eli Therapeutic antibody formulation.
CN112618482A (en) * 2019-09-24 2021-04-09 江苏恒瑞医药股份有限公司 Novel protein formulations
CN112741804A (en) * 2019-10-31 2021-05-04 上海君实生物医药科技股份有限公司 Stable formulations containing anti-PD-L1 antibodies
CN113116812A (en) * 2019-12-30 2021-07-16 百奥泰生物制药股份有限公司 Preparation containing anti-Trop2 antibody-drug conjugate as well as preparation method and application thereof
CN117088974B (en) * 2023-08-14 2024-02-13 武汉健昊生物科技有限公司 Antibody preservation solution

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003009817A2 (en) * 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
WO2003070760A2 (en) * 2002-02-20 2003-08-28 F. Hoffmann-La Roche Ag Anti-amyloid beta antibodies and their use
US20030202972A1 (en) * 1995-07-27 2003-10-30 Genentech, Inc. Protein formulation
US20040197324A1 (en) * 2003-04-04 2004-10-07 Genentech, Inc. High concentration antibody and protein formulations
WO2006081587A2 (en) * 2005-01-28 2006-08-03 Wyeth Stabilized liquid polypeptide formulations
WO2006083689A2 (en) * 2005-01-28 2006-08-10 Elan Pharma International Limited Anti a beta antibody formulation
WO2007068429A1 (en) * 2005-12-12 2007-06-21 F. Hoffmann-La Roche Ag Antibodies against amyloid beta 4 with glycosylated in the variable region
WO2007110339A1 (en) * 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Anti-igf-1r human monoclonal antibody formulation

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030202972A1 (en) * 1995-07-27 2003-10-30 Genentech, Inc. Protein formulation
WO2003009817A2 (en) * 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
WO2003070760A2 (en) * 2002-02-20 2003-08-28 F. Hoffmann-La Roche Ag Anti-amyloid beta antibodies and their use
US20040197324A1 (en) * 2003-04-04 2004-10-07 Genentech, Inc. High concentration antibody and protein formulations
WO2006081587A2 (en) * 2005-01-28 2006-08-03 Wyeth Stabilized liquid polypeptide formulations
WO2006083689A2 (en) * 2005-01-28 2006-08-10 Elan Pharma International Limited Anti a beta antibody formulation
WO2007068429A1 (en) * 2005-12-12 2007-06-21 F. Hoffmann-La Roche Ag Antibodies against amyloid beta 4 with glycosylated in the variable region
WO2007110339A1 (en) * 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Anti-igf-1r human monoclonal antibody formulation

Cited By (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US10464976B2 (en) 2003-01-31 2019-11-05 AbbVie Deutschland GmbH & Co. KG Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8008073B2 (en) 2003-12-12 2011-08-30 Chugai Seiyaku Kabushiki Kaisha Anti-Mpl antibodies
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
US9777066B2 (en) 2005-06-10 2017-10-03 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
US9241994B2 (en) 2005-06-10 2016-01-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US10208109B2 (en) 2005-11-30 2019-02-19 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
US10323084B2 (en) 2005-11-30 2019-06-18 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9951125B2 (en) 2006-11-30 2018-04-24 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US9585956B2 (en) 2007-06-12 2017-03-07 Ac Immune S.A. Polynucleotides encoding anti-amyloid beta monoclonal antibodies
US9175094B2 (en) 2007-06-12 2015-11-03 Ac Immune S.A. Monoclonal antibody
US9146244B2 (en) 2007-06-12 2015-09-29 Ac Immune S.A. Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US11981743B2 (en) 2008-03-14 2024-05-14 Biocon Limited Monoclonal antibody and a method thereof
US10669346B2 (en) 2008-03-14 2020-06-02 Biocon Limited Monoclonal antibody and a method thereof
US10000573B2 (en) 2008-03-14 2018-06-19 Centro De Immunologia Molecular Monoclonal antibody and a method thereof
JP2017071627A (en) * 2008-06-20 2017-04-13 ノバルティス アーゲー Immunoglobulin with reduced aggregation
US20100074903A1 (en) * 2008-09-19 2010-03-25 Ulla Grauschopf Novel antibody formulation
US9993552B2 (en) 2008-10-29 2018-06-12 Ablynx N.V. Formulations of single domain antigen binding molecules
US10118962B2 (en) 2008-10-29 2018-11-06 Ablynx N.V. Methods for purification of single domain antigen binding molecules
US11370835B2 (en) 2008-10-29 2022-06-28 Ablynx N.V. Methods for purification of single domain antigen binding molecules
RU2481824C2 (en) * 2008-10-29 2013-05-20 Аблинкс Н.В Preparations of single domain antigen-binding molecules
RU2683861C2 (en) * 2008-10-29 2019-04-02 Аблинкс Н.В. Formulations of single domain antigen binding molecules
US9393304B2 (en) 2008-10-29 2016-07-19 Ablynx N.V. Formulations of single domain antigen binding molecules
JP2012509269A (en) * 2008-11-17 2012-04-19 ジェネンテック， インコーポレイテッド Methods and formulations for reducing polymer aggregation under physiological conditions
EP2358395A1 (en) * 2008-11-17 2011-08-24 F. Hoffmann-La Roche AG Method and formulation for reducing aggregation of a macromolecule under physiological conditions
EP2358395A4 (en) * 2008-11-17 2013-11-20 Hoffmann La Roche Method and formulation for reducing aggregation of a macromolecule under physiological conditions
JP7286595B2 (en) 2008-12-10 2023-06-05 ノバルティス アーゲー Antibody formulation
JP2018168158A (en) * 2008-12-10 2018-11-01 ノバルティス アーゲー Antibody formulation
JP2015231997A (en) * 2008-12-10 2015-12-24 ノバルティス アーゲー Antibody formulation
JP2020203889A (en) * 2008-12-10 2020-12-24 ノバルティス アーゲー Antibody formulation
JP2012511540A (en) * 2008-12-10 2012-05-24 ノバルティス アーゲー Antibody preparation
WO2010069858A1 (en) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
WO2010100179A2 (en) * 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2010100179A3 (en) * 2009-03-05 2011-05-12 Novartis Ag Self-forming gel system for sustained drug delivery
CN102770157A (en) * 2009-11-20 2012-11-07 拜康有限公司 Formulations of antibody
EP3721904A1 (en) * 2009-11-20 2020-10-14 Biocon Limited Formulations of t1h antibody
WO2011061712A1 (en) * 2009-11-20 2011-05-26 Biocon Limited Formulations of antibody
JP2016104780A (en) * 2009-11-20 2016-06-09 バイオコン リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ Antibody formulation
JP2013511510A (en) * 2009-11-20 2013-04-04 バイオコン リミテッド Antibody preparation
JP2013515754A (en) * 2009-12-29 2013-05-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Novel antibody formulation
KR20190011326A (en) 2010-01-20 2019-02-01 추가이 세이야쿠 가부시키가이샤 Stabilized antibody-containing liquid formulations
KR20180000339A (en) 2010-01-20 2018-01-02 추가이 세이야쿠 가부시키가이샤 Stabilized antibody-containing liquid formulations
KR20200062393A (en) 2010-01-20 2020-06-03 추가이 세이야쿠 가부시키가이샤 Stabilized antibody-containing liquid formulations
EP3378486A2 (en) 2010-01-20 2018-09-26 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing liquid formulations
US11612562B2 (en) 2010-01-20 2023-03-28 Chugai Seiyaku Kabushiki Kaisha Solution preparation containing stabilized antibody
US10022319B2 (en) 2010-01-20 2018-07-17 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing liquid formulations
EP3892292A2 (en) 2010-01-20 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing liquid formulations
KR20220054725A (en) 2010-01-20 2022-05-03 추가이 세이야쿠 가부시키가이샤 Stabilized antibody-containing liquid formulations
WO2011090088A1 (en) 2010-01-20 2011-07-28 中外製薬株式会社 Solution preparation containing stabilized antibody
EP3216462A2 (en) 2010-02-26 2017-09-13 Novo Nordisk A/S Stable antibody containing compositions
EP3409289A2 (en) 2010-02-26 2018-12-05 Novo Nordisk A/S Stable antibody containing compositions
US9795674B2 (en) 2010-02-26 2017-10-24 Novo Nordisk A/S Stable antibody containing compositions
WO2011104381A2 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
EP3708190A1 (en) 2010-02-26 2020-09-16 Novo Nordisk A/S Stable antibody containing compositions
US10709782B2 (en) 2010-02-26 2020-07-14 Novo Nordisk A/S Stable antibody containing compositions
USRE47150E1 (en) 2010-03-01 2018-12-04 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
US9211330B2 (en) 2010-03-03 2015-12-15 Ablynx N.V. A-beta binding polypeptides
US9822171B2 (en) 2010-04-15 2017-11-21 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2011147921A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
US10835602B2 (en) 2010-05-28 2020-11-17 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US10047121B2 (en) 2010-08-14 2018-08-14 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2012028683A1 (en) * 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
AU2017204192B2 (en) * 2011-05-02 2019-09-12 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
EP3311834A1 (en) * 2011-05-02 2018-04-25 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
US10143752B2 (en) 2011-05-02 2018-12-04 Millennium Pharmaceuticals, Inc. Methods of treating ulcerative colitis
WO2012151247A3 (en) * 2011-05-02 2013-02-28 Millennium Pharmaceuticals, Inc. FORMULATION FOR ANTI-α4β7 ANTIBODY
US10004808B2 (en) 2011-05-02 2018-06-26 Millennium Pharmaceuticals, Inc. Methods of treating ulcerative colitis
US10040855B2 (en) 2011-05-02 2018-08-07 Millennium Pharmaceuticals, Inc. Formulation for anti-α4β7 antibody
US11560434B2 (en) 2011-05-02 2023-01-24 Millennium Pharmaceuticals, Inc. Formulation for anti-α4β7 antibody
US9663579B2 (en) 2011-05-02 2017-05-30 Millennium Pharmaceuticals, Inc. Formulation for anti-α4β7 antibody
AU2019216679B2 (en) * 2011-05-02 2021-09-23 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
AU2012250872B2 (en) * 2011-05-02 2017-07-13 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
EA032625B1 (en) * 2011-05-02 2019-06-28 Милленниум Фармасьютикалз, Инк. FORMULATION FOR ANTI-α4β7 ANTIBODY
US9764033B2 (en) 2011-05-02 2017-09-19 Millennium Pharmaceuticals, Inc. Formulation for anti-α4β7 antibody
US10517830B2 (en) 2011-10-25 2019-12-31 Prothena Biosciences Limited Antibody formulations and methods
US9089529B2 (en) 2011-10-25 2015-07-28 Prothena Therapeutics Limited Antibody formulations and methods
US9884020B2 (en) 2011-10-25 2018-02-06 Prothena Therapeutics Limited Antibody formulations and methods for treating AL amyloidosis
WO2013131866A1 (en) * 2012-03-08 2013-09-12 F. Hoffmann-La Roche Ag Abeta antibody formulation
CN104159613A (en) * 2012-03-08 2014-11-19 霍夫曼-拉罗奇有限公司 Abeta antibody formulation
KR20140120942A (en) * 2012-03-08 2014-10-14 에프. 호프만-라 로슈 아게 Abeta antibody formulation
AU2013229613B2 (en) * 2012-03-08 2015-07-30 F. Hoffmann-La Roche Ag Abeta antibody formulation
KR101666289B1 (en) * 2012-03-08 2016-10-13 에프. 호프만-라 로슈 아게 Abeta antibody formulation
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10525130B2 (en) 2012-03-26 2020-01-07 Sanofi Stable IGG4 based binding agent formulations
EP2841561B1 (en) 2012-04-24 2019-01-16 F.Hoffmann-La Roche Ag Cell culture compositions and methods for polypeptide production
US9849181B2 (en) 2012-08-31 2017-12-26 Bayer Healthcare Llc High concentration antibody and protein formulations
WO2014036071A1 (en) * 2012-08-31 2014-03-06 Bayer Healthcare Llc Antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US11028168B2 (en) 2013-07-23 2021-06-08 Biocon Limited Use of a CD6 binding partner and method based thereon
US10189899B2 (en) 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
US10413593B2 (en) 2014-10-24 2019-09-17 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and GLP-1 receptors
WO2016205037A1 (en) * 2015-06-17 2016-12-22 Eli Lilly And Company Anti-cgrp antibody formulation
EA037580B1 (en) * 2015-06-17 2021-04-16 Эли Лилли Энд Компани Anti-cgrp antibody formulation
US11498959B2 (en) 2015-06-17 2022-11-15 Eli Lilly And Company Anti-CGRP antibody formulation
US11584793B2 (en) 2015-06-24 2023-02-21 Hoffmann-La Roche Inc. Anti-transferrin receptor antibodies with tailored affinity
WO2017051273A1 (en) * 2015-09-22 2017-03-30 Pfizer Inc. Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
RU2779389C2 (en) * 2015-09-22 2022-09-06 Пфайзер Инк. Method for production of therapeutic protein preparation, and preparation based on antibodies, obtained by such a method
AU2016329034B2 (en) * 2015-09-22 2019-05-23 Pfizer Inc. Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
US11603411B2 (en) 2015-10-02 2023-03-14 Hoffmann-La Roche Inc. Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
US10933141B2 (en) 2015-12-30 2021-03-02 Genentech, Inc. Formulations with reduced degradation of polysorbate
US10525137B2 (en) 2015-12-30 2020-01-07 Genentech, Inc. Formulations with reduced degradation of polysorbate
US11242401B2 (en) 2016-10-21 2022-02-08 Biocon Limited Monoclonal antibody and a method of use for the treatment of lupus
CN108373494A (en) * 2018-02-27 2018-08-07 武汉伊艾博科技有限公司 A kind of protection technique preventing Proteolysis of recombinant proteins
WO2022072255A1 (en) * 2020-09-30 2022-04-07 Merck Sharp & Dohme Corp. Binding proteins and antigen binding fragments thereof that bind abeta

Also Published As

Publication number Publication date
KR20090104017A (en) 2009-10-05
PE20081477A1 (en) 2008-10-18
RU2009126420A (en) 2011-01-20
NO20092586L (en) 2009-07-17
TW200831133A (en) 2008-08-01
AU2007331712A1 (en) 2008-06-19
JP2010512356A (en) 2010-04-22
ZA200904014B (en) 2010-04-28
MA30975B1 (en) 2009-12-01
US20110070225A1 (en) 2011-03-24
AR064220A1 (en) 2009-03-18
CA2671968A1 (en) 2008-06-19
ECSP099403A (en) 2009-07-31
IL198963A0 (en) 2011-08-01
CR10823A (en) 2009-08-12
CL2007003583A1 (en) 2008-07-18
CN101553504A (en) 2009-10-07
EP2094729A1 (en) 2009-09-02
MX2009006199A (en) 2009-06-22
BRPI0721097A2 (en) 2014-07-01
AU2007331712A2 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
US20110070225A1 (en) Beta antibody parenteral formulation
RU2731418C2 (en) Stable pharmaceutical preparation based on the pd-1 antibody and its use in medicine
EP2822587B1 (en) Abeta antibody formulation
CA2781467C (en) Formulations of antibody
CN105339004B (en) anti-IL-4/anti-IL-13 bispecific antibody formulations
US9457089B2 (en) Highly concentrated aqueous protein solution with reduced viscosity
US20110158987A1 (en) Novel antibody formulation
US20090068196A1 (en) Pharmaceutical formulation of an antibody against IL13Ralpha1
TWI734233B (en) Antibody formulation
JP2021178862A (en) Protein formulations
JP2020534255A (en) Process for lyophilized pharmaceutical formulations of therapeutic proteins
US20090208509A1 (en) Pharmaceutical formulation of an antibody against IL-1R
US11912764B2 (en) Anti-connexin antibody formulations
US20130251725A1 (en) Anti-P-Selectin Antibody Formulation
JPWO2008029908A1 (en) Stable lyophilized pharmaceutical formulation containing antibody
US20170137535A1 (en) Anti-factor d antibody formulations

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780045586.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07856573

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: CR2009-010823

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 577163

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 198963

Country of ref document: IL

Ref document number: 09053707

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 12009501079

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2671968

Country of ref document: CA

Ref document number: 2009060872

Country of ref document: EG

ENP Entry into the national phase

Ref document number: 2009540650

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 3312/CHENP/2009

Country of ref document: IN

Ref document number: MX/A/2009/006199

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007331712

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007856573

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020097013954

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2007331712

Country of ref document: AU

Date of ref document: 20071211

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009126420

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12448190

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0721097

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090612